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Abstract

Current progress in the development of vaccines has decreased
the incidence of fatal and non-fatal infections and increased longevity.
However, new technologies need to be developed to combat an
emerging generation of infectious diseases. DNA vaccination has been
demonstrated to have great potential for use against a wide variety of
diseases. Alone, this vaccine technology does not generate a
significant immune response for vaccination, but combined with
delivery by electroporation (EP), can enhance plasmid expression and
immunity against the expressed antigen. Most EP systems, while
effective, can be invasive and painful making them less desirable for
use in vaccination. Our lab recently developed a non-invasive
electrode known as the multi-electrode array (MEA), which lies flat on
the surface of the skin without penetrating the tissue.

This study

evaluated the use of the MEA for the development of DNA vaccines.
We assessed the appropriate delivery conditions for gene expression
and the development of humoral immunity. We used both B. anthracis
and HBV as infectious models for our experiments. Our results
indicated that the MEA can enhance gene expression in a mouse model
xi

with minimal to no tissue damage. Optimal delivery conditions, based
on generation of antibodies, were determined to be 125-175V/cm and
150ms with 200ug and a prime boost protocol administered on Day 0
and 14. Under these conditions, end-point titers of 20,000-25,000
were generated. Neutralizing antibodies were noted in 40-60% of
animals.
Additionally, we utilized a guinea pig model to assess the
translation potential of this electrode. The plasmid encoding HBsAg,
pHBsAg, was delivered intradermally with the MEA to guinea pig skin.
The results show increased protein expression resulting from plasmid
delivery using the MEA as compared to injection alone. Within 48
hours of treatment, there was an influx of cellular infiltrate in the
experimental groups. Humoral responses were also increased
significantly in both duration and intensity as compared to the injection
only groups. Results from both experimental models demonstrate that
protective levels of humoral immunity can be generated and that this
electrode should translate well to the clinic.

xii

Introduction
Vaccine Development - history
The development of vaccines is arguably one of the most
important medical advancements of the 20th century. However,
humans have been attempting passive protection from disease since
500BC. The Chinese developed the first passive vaccines and since
then our knowledge base has grown to allow us to develop more
sophisticated technologies for fighting infectious disease. From the
“black plague,” to diseases like small pox, whooping cough,
tuberculosis, measles, and influenza which at times decimated much of
the world's population. The intentional development of vaccines
became a reality when it was noted that milk maids exposed to
cowpox did not become sick from small pox. This was the first modern
recognition that passive protection from disease could be achieved and
intentionally transferred. Prior to that Robert Koch developed his
postulates based on the findings and identification of anthrax.
This led to a whole new era of vaccine development. The advent
of the US Centers for Disease Control and Prevention was in direct
response to help citizens understand their role in preventing disease.
1

Mass communications on posters and radio spread messages to keep
your hands clean and stay indoors when sick. The mid-20th century
gave rise to advancements in the area of bacteriology and infection
disease. Additionally, the development technologies that would allow
us to better diagnose and combat infectious diseases spurred
advancements of vaccines against common agents like measles,
mumps, and rubella, and whooping cough. Several of these vaccines
were made mandatory by the US government to prevent further
fatalities and spreading of the infections. The limitation that science is
continually faced with is emerging infections where traditional methods
of vaccinations have been unsuccessful. Development of vaccines has
since sputtered but several methods have been developed that show
promise for continued use against emerging infections
DNA Vaccines
DNA vaccines are genetically engineered plasmid DNA that
encode for antigenic proteins under the control of a eukaryotic
promoter. The most important parts of the plasmid are the promoter
(most commonly CMV, RSV, SV40, and LTR used to drive constant
stable expression in mammalian cells), the transgene (the gene of
interest for vaccination), and the polyadenlyation sequence
(responsible for mRNA stability and translation). The basic mechanism
of DNA vaccination is that the DNA is injected into the tissue (muscle,
2

skin, subcutaneous space, etc) and enters the host cell. The DNA is
translocated to the nucleus where transcription and translation occur
to generate the target protein. The peptides are then presented on
the cell surface by MHC I, or secreted (depending on the construction
of the plasmid). The presented protein is then picked up and
undergoes immune stimulation by APCs [2].
There are several advantages to using DNA vaccines over more
traditional vaccination methods. First, DNA is highly stable, relatively
easily produced, and stored [3-5]. Secondly, DNA vaccines can induce
humoral and cellular immunity like live attenuated vaccines without
the risk of reversion [6, 7]. Third, they have been demonstrated to
have fewer side effects. Fourth, DNA vaccines can be multivalent,
expressing multiple antigenic components on a single vaccine which
could be useful for vaccinating against multiple agents simultaneously
or agents multiple subunits of the same antigen [3-5]. Finally the use
of DNA vaccines prevents the need for cold chain storage of vaccines
during transport.
Initial studies into DNA vaccination began in the early 90’s when
Wolf et al demonstrated that DNA could be taken up by muscle cells
and that integration into mouse genomic DNA did not occur [8]. These
data opened up a whole new world for DNA vaccines to take off.
Shortly thereafter several studies were conducted evaluating the
3

development of immunity from DNA vaccination. It was reported that
mice injected with Influenza DNA encoding for the highly conserved
nucleoprotein were protected from lethal challenge [9]. In this study
both induction of humoral and cell mediated immunity was noted
though protection was correlated to CMI. Since this study, several
infectious agents have been tested for development of vaccination
(Table 1). Many of these studies have been focused on viral
pathogens like: HIV, HBV, HSV, LCMV and Rabies Virus. The use of
DNA vaccination has also been evaluated for the development of
immunity against parasitic infections like: Plasmodium falciparum and
Leishmania donovani; as well as bacterial pathogens like:
Mycobacterium tuberculosis and Clostridium tetani.
A variety of animal models have also been utilized to study DNA
vaccination and the subsequent development of immunity. The most
common has been the mouse model where initial studies were
conducted as described earlier, but also continues to be the most
common model for ease of use and reagent availability. However,
several other models have been used including: cattle, rabbits, dogs,
rats, guinea pigs, and NHP’s with varying degrees of success.
Delivery of DNA is an important consideration development of
immunity. The primary injection site for DNA vaccination has been
muscle. This is primarily because early studies demonstrated that
4

direct injection into the muscle was superior to other tissue types [10]
and that it was superior to adenoviral vectors [11]. This is most likely
due to the long turnover of myocytes and their post mitotic state [12].
Despite the success of these results the preclinical models did not line
up with initial human clinical trials [13]. For DNA vaccination to
become a reality improved delivery systems were necessary to
develop.
Table 1. DNA vaccines against infectious agents.
Viruses
HIV [121, 122]

Bacteria
Borrellia burgdorferi
[123, 124]
SARS [126-128]
Clostridium tetani
[129]
Influenza[133-135] Mycobacterium
tuberculosis [136140]
Rabies Virus[147,
Bacillus anthracis
148]
[149, 150]
HBV [152-154]
Clostridium
botulinum [155,
156]
HCV [159, 160]
Ebola Virus [161]
HSV[162, 163]
HPV [164]
WNV [165]
Rotavirus [166, 167]
St. Louis
Encephalitis Virus
[168]

Parasites
Plasmodium
falciparum [125]
Leishmania major/
donovani [130-132]
Toxoplasma gondii
[141-146]
Tania Ovis [151]
Schistosoma mansoni
[157, 158]

*Pubmed keywords: DNA vaccine, Infectious disease
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Electroporation
EP requires the application of electric fields causing
permeabilization of the cell membranes [14, 15]. While there is still
much unknown about the exact mechanisms of DNA entry into cell,
what is understood is that it is a complex process involving interaction
of the DNA with the cell membrane and that the DNA makes its way to
the nucleus once inside the cell where it undergoes transcription and
translation. At the time of EP pulsing, the DNA may be taken up by
several processes, but one idea is that small “pores” are created in the
membrane [15]. These holes are transient and are resolved very
quickly; therefore, the DNA must be present at the time of pulsing.
The resolution of the membrane pores allows the cell to continue to
undergo normal cell function and processing including
transcription/translation of the DNA.
Initial studies evaluating in vivo EP for transgene delivery and
expression were performed on rat brain tumors [16] and rat livers
[17]. Those studies demonstrated enhanced delivery and expression
of plasmid DNA from EP mediated delivery. Further experimentation
revealed that transgene expression could be increased 100-1000 fold
from muscle EP stimulation [18-20]. Similar fold enhancements have
also been seen in skin tissues ranging from 10-1000 fold [1].
Successful EP mediated DNA delivery has been demonstrated in most
6

tissue types and for several therapeutic and prophylactic indications
such as cancer therapy, infectious diseases, wound healing, metabolic
disorders and vaccines [21]. Recently several US clinical trials have
been initiated. Eight clinical trials have been completed using EP,
three assessing EP devices for use against infectious agents. 21
others are currently active or recruiting. 12 of those are involving DNA
vaccination against infectious agents (clinicaltrials.gov; Keyword:
Electroporation).
Electrically enhanced DNA vaccinations
Initial in vivo EP DNA vaccine studies evaluated gene expression
and immune stimulation from delivery of plasmids encoding either HBV
protein or HIV protein, gag, to the muscle. Their results confirmed
that increased humoral responses to HBV [22] and cellular [23]
immune response to HIV gag from EP compared to injection only (IO)
of plasmid DNA. More recent studies have broadened the list of
pathogens which EP has been successfully used in vivo to include other
viral pathogens such as: HIV [24-27], SARS-CoV [28, 29], Influenza
[30-34], WNV and JEV [35, 36], as well as HBV, HCV [37-41] and HPV
[42, 43]. EP delivered DNA vaccines expressing proteins of the
parasitic infection Plasmodium falciparum, one of the parasites causing
malaria [44], as well as bacterial infections like Bacillus anthracis [45],
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Clostridium botulinum [46], and Mycobacterium tuberculosis [47] have
also been demonstrated to enhance immunogenicity. These results
demonstrate the capacity of EP to enhance not only gene delivery and
protein expression but also its ability to stimulate the host immune
response against a wide variety of pathogens.
Target tissues for electrically mediated DNA Vaccine delivery
Currently, electrically mediated delivery of DNA vaccines
typically employ painful invasive needle electrodes that are inserted
into the muscle for electrical stimulation. The primary tissue used for
in vivo EP is muscle because it is accessible, highly vascularized,
multinucleated, and expresses DNA for long periods of time due to the
post-mitotic nature of the tissue [12]. However, pain associated with
administration is not desirable. As such, alternative delivery sites and
methods have been explored. The skin is an attractive target for
vaccination because of the high proportion of APC’s and a large surface
area. Recent studies, as well as work done in our laboratory,
demonstrated that intradermal electrically mediated DNA expression
can be increased both locally and systemically [48-53]. Electrodes
developed for skin EP include: caliper, plate, tweezer, and clip
electrodes as well as several needle electrodes [54-58].

8

Table 2. In vivo Electrically Mediated DNA
vaccines against infectious
HIV/ SIV [23-27]
SARS [28, 29]
Influenza [30-34]
WNV [35]
JEV [36]
HBV and HCV [37-41]
HPV [42, 43]
Plasmodium falciparum [44]
Bacillus anthracis [45]
Clostridium botulinum [46]
Mycobacterium tuberculosis
[47]
*Pubmed keywords: Electroporation and DNA vaccine or
Electrically Mediated DNA vaccine.

The skin as a target for delivery
The skin is a highly complex and immunogenic organ. It is the
largest organ in the body, and well equipped for recognizing and
defending against infection. Its primary functions are to defend
against infection and insulate and regulate temperature as well as
regulating absorption and fluid loss and sensation. Human skin varies
in thickness from about 0.5mm on the eyelids to 4mm on the hands
and soles of the feet, with the majority of skin being between 1 and
2mm. The skin structure is made up of three layers: the epidermis,
the dermis, and the subcutaneous layers. The epidermis consists
primarily of keratinocytes, but also contains melanocytes and
epidermal dendritic cells known as langerhans cells. It is made up of
9

five strata: stratum corneum, lucidum, granulosum, spinosum,
basale. Cells are formed at the basale membrane and migrate up the
strata changing shape and composition until they reach the stratum
corneum where they are sloughed off. The rate of turnover is
approximately 27 days [59]. The dermis, the main candidate for
injection of DNA in the skin, consists of fibroblasts and dermal
dendritic cells (highly efficient antigen presenting cells). In this layer,
the hair follicles, sweat glands and blood vessels are found. The
subcutaneous layer consists of connective tissue and fat. The primary
cell types are fibroblasts, macrophages and fat cells [60].

10

Figure 1. Human Skin Structure. Cartoon image of human
skin, showing epidermis, dermis and subcutaneous layer.
Also represented are hair follicles and the basement
membrane. Image from www.skininfo.org.
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Animal models for skin delivery
Several animals have been used for skin research including:
mouse pigs, rabbits, guinea pigs, rats, and NHP’s. The most common
is the mouse, though this model has several disadvantages when
compared to human skin. Mice have very thin skin, lots of hair
follicles, and have a panniculus carnosus (layer of muscle beneath the
dermis, not present in human skin). A better model for comparison to
human skin is the guinea pig. Guinea pigs have langerhans cells in the
epidermis, a dermal elastic fiber network, and contain fibroblasts,
monocytes, and macrophages. A second model considered good for
comparison to human skin is the pig

Pigs have a thick epidermis, a

spare hair coat, well differentiated papillary body in the dermis and
elastic fiber network [61, 62]. An equally appropriate small rodent
model is the Hairless guinea pig. This model in addition to having the
same benefits as the traditional haired guinea pig also has a thick
epidermis with distinct strata, serrated/non-serrated basal
keratinocytes, a papillary dermal layer, and superficial
microvasculature [63]

12

Electrode development for the skin
Several types of electrodes have been developed for use in the
skin. These electrodes include: NPE’s like plate, tweezer and caliper
electrodes as well as PE and microneedle electrodes. Both types
consist of single or multiple electrodes in various conformations
intended to optimize plasmid delivery and expression [60].
Penetrating Electrodes
Penetrating skin electrodes consist of needle electrodes in
various configurations. The PE’s utilized in the skin were reviewed
thoroughly by Gothelf et al [60] and included in Table 4 below. These
electrodes range in electric fields (50-1800 V/cm), duration (50us to
650ms) and pulse number (1-18) depending on electrode design. The
success of this type of electrode was recently published demonstrating
the effective enhancement of transgene production in porcine skin
[64]. Several PE’s have been evaluated for the development of
immunity against various infectious agents [60]. The most recent of
these have demonstrated enhanced humoral and cell mediated
immunity in comparison to DNA alone.
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Non-Penetrating electrodes
NPE’s have also been utilized for skin EP and provide the
advantage of not being inserted into the skin. Early NPE’s consisted
primarily of two plated electrodes like caliper and tweezer electrodes
that were squeezed to contact the skin surface. This generated
variability in the distance between plates when applying pulses. While
these electrodes were somewhat effective, experimentation revealed
that DNA uptake and expression could be increased by applying
electrical pulses in multiple directions. Therefore the Heller lab
designed the 4PE. This electrode consisted of four plates with a nonconductive stopper that held the distance between the plates constant
reducing variability when pulsing. The Heller lab found that expression
using this electrode was significantly increased over IO and was
consistent with other plate electrodes. However, due to the 6mm
distance between the plates in this electrode the absolute voltage
necessary for optimal expression generated pain.

14

Table 3.

Published Non-Penetrating Electrodes.

Plate Electrode- Adjustable or Fixed Distance
Reference

Voltage

Duration

Number

Titomirov 1991

400-600V/cm

100- 300µs

2

Zhang 1996

120V

10-20ms

3

Drabick 2001

1750V

100µs

6

Heller 2001

100V/cm

20ms

8

1500V/cm

100µs

8

Lucas 2001

100V/cm

20ms

8

1500V/cm
750 + 14 +
EEPV/cm

100µs
50µs + 20ms +
20ms

8
2+4+
1

Maruyama 2001

12- 24V

50ms

8

Chesnoy 2002

200-400V/cm

20ms

10

Zhang 2002

50-100V

15-30ms

3 to 30

75V

20ms

1 to 12

100V/cm

2ms

60

Lee 2004

200-400V/cm

20ms

6

Medi 2005

50V

30ms

10

100V/cm

10-30ms

5

100-300V

10ms

5

200V/cm

400ms

1

250V/cm

20ms

6

1000V/cm

100µs

1

1750V/cm
1000 + 140200V/cm

100µs

6

100µs + 400ms

1+1

Pavselj 2005

700 + 200V/cm

100µs + 400ms

1+1

Thanaketpaisarn
2005

50-1000V/cm

5ms

12

Gao 2007

800V/cm

20ms

6

Heller 2007

100V/cm

2ms

8

Vandermeulen 2007

100µs + 400ms

1+1

Andre 2008

700 + 200V/cm
1000 + 80200V/cm

100µs + 400ms

1+1

Vandermeulen 2009

700 + 200V/cm

100µs + 400ms

1+1

Gothelf 2011

1000 + 100V/cm
1000 + 80160V/cm

100µs + 400ms

1+1

100µs + 400ms

1+1

Gothelf 2011

*Table continues on next page. Table reconstructed from
Gothelf et al 2011 [60]
15

Table 3 cont.
Wires on skin- Custom built clips- Flat patches- MEA- 4PE
Dujardin 2001

335V

0.5ms

10

335V

5ms

10

1000V/cm

100µs

10

Heller 2001

1500V/cm

100µs

8

Zhang 2002

75V

20ms

6

Babiuk 2003

60-80V

60ms

6

Heller 2007

10-1500V/cm

0.1-2000ms

8

Pedron-Mazoyer 2007

60-240V

20ms

8

Heller 2008

100V/cm

150ms

8

Mazeres 2009

60-240V

20ms

8

Heller 2009

100- 300V/cm

150-300ms

4

*Table reconstructed from Gothelf et al 2011 [60]
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Table 4.

Published Penetrating Electrodes.

Needle Electrodes- Needle Arrays
Reference
Glasspool- Malone
2000

1750V/cm

100µs

6

Drabick 2001

1500V/cm

100µs

2 to 6

1750V/cm

100µs

2 to 6

2000V/cm

100µs

2 to 6

200-400V/cm

20ms

6

400-1800V/cm

20ms

6

1750V/cm

100µs

6 to 18

Marti 2004

1800V/cm

100µs

6

Lin 2006

1800V/cm

100µs

6

Roos 2006

200V/cm

100µs

6

275V/cm

10ms

8

1125V/cm

50µs

2

1750V/cm

100µs

6

1125 + 275V/cm

50µs + 10ms

2+8

Zhao 2006

200V/cm

650ms

*

Kang 2008

50-250V/cm

100ms

6

Liu 2008

400V/cm

20ms

10

Brave 2009

1125 + 275V/cm

50µs + 10ms

2+8

Ferraro 2009

200V/cm

20ms

8

Lladser 2009

1125 + 275V/cm

50µs + 10ms

2+8

Byrnes 2004

Voltage

Duration

Number

Roos 2009

1125 + 275V/cm 50µs + 10ms 2 + 8
1000 + 8100µs +
Gothelf 2011
140V/cm
400ms
1+1
Needles Parallel to Skin Surface- Syringes- Plate and Fork
Electrodes
Maruyama 2001

12-50V

50ms

8

Lee 2004

50-200V/cm

20ms

6

*Table reconstructed from Gothelf et al 2011 [60]
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Multielectrode Array
The MEA was designed to improve upon the 4PE. It is a 16
electrode array with 2mm spacing between electrodes. The reduced
distance between electrodes decreases the absolute voltage applied
while maintaining the electric Field (V/cm). For example, using the
4PE an electric field of 300V/cm would equate to applying an absolute
voltage of 180 Volts (V=EF * (6/10)), whereas that same electric field
would equate to an absolute voltage of 60 Volts (V=EF * (2/10)) using
the MEA.
Our initial publications using the MEA to enhance gene
expression demonstrated that the MEA was capable of inducing similar
gene expression in guinea pigs and rats as conventional electrodes and
that the level of expression was related to the duration and field
strength applied[55, 65]. GFP results, demonstrate that expression
was contained within the epidermis [1]. Muscle twitching from
treatment was greatly reduced in both guinea pigs and rats [1, 55].
Finally, tissue damage from treatment was minimal and completely
recoverable in 1 to 2 weeks [1].
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Figure 2. Non-invasive
Multielectrode array. The MEA
is designed with 16 electrodes
spaced 2mm apart in a 4X4
square. The electrodes are round
and gold plated with flat heads.
[1]
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Infectious Disease Models
Bacillus anthracis
Bacillus anthracis is a gram positive spore forming rod-shaped
bacterium. In vivo the rods appear in short chains surrounded by a
polypeptide capsule [66]. The Centers for Disease Control and
Prevention classify B. anthracis as a category A agent because it “can
be easily disseminated or transmitted from person to person, results in
high mortality rates and have the potential for major public health
impact, might cause public panic and social disruption, and requires
special action for public health preparedness.”

It is found readily in

soil and was historically a disease of livestock. Full virulence requires
an anti-phagocytic capsule, and three toxin proteins.
Sporulation occurs from the presence of nutrient limited
environment. In the case of B. anthracis, spores have been
demonstrated to survive for decades and are demonstrated to aid in
dissemination of bacterium. The spore structure is made up of five
parts: the core, cortex, coat, innerspace, and the exosporium. The
exosporium contains several proteins that may play a role in
vaccination. One exosporium B. anthracis protein that has been
extensively studied is Bacillus collagen like protein A. This protein has
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been shown to function in mediating the specificity of B. anthracis
spores to be taken up by macrophages [67, 68]
There are two toxins produced by B. anthracis that are of
importance for clinical disease progression. They are edema toxin and
lethal toxin. These binary toxins are comprised of protective antigen
(PA) and either edema factor (EF) or lethal factor (LF) all produced
after spore germination. The protective antigen protein is an 83Kda
protein in its inactive state. It is cleaved by furin-like proteases to its
63Kda active [69]. Several active PA’s come together to form either
the heptameric or the highly stable octameric (common under normal
physiologic pH and temperatures) prepore [70-72]. Multiple copies of
the LF and EF bind to the PA prepore and are endocytosed and
transferred into an acidic compartment. The PA prepore channel
undergoes a conformation change and insert into the membrane
forming a cation selective channel. The PA channel unfolds and using
gradient that develops across the endosomal membrane translocates
LF and EF into the cytosol [73-75]
Edema toxin is a calmodulin-dependent adenylate cyclase that
alters water homeostasis causing edema and impairs neutrophil
function, rendering the host further susceptible to infection [76].
Lethal toxin leads to the release of reactive oxygen intermediates as
well as the production of proinflammatory cytokines tumor necrosis
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factor and interleukin-1b responsible for rapid circulatory collapse
leading to disruption of MAPKK pathways and cell death [77, 78].
Clinical disease
B. anthracis causes anthrax disease, originally known as woolsorters, because it was those individuals that primarily acquired the
disease from spore infested wool. Anthrax has three clinical
manifestations. The first, cutaneous anthrax, acquired through a break
in the skin, is usually self-limiting. This form of anthrax is estimated
to account for greater than 90% of human anthrax cases in the world
[79]. The second and slightly more severe is gastrointestinal, which is
acquired through ingestion of infected meat. Mortality rates with
antibiotic treatment are about 40% [66]. The final and most life
threatening form, known as pulmonary anthrax, is caused by inhaling
B. anthracis spores into the lungs. Upon inhalation spores are taken
into the alveolar spaces and engulfed by alveolar macrophages. They
are transferred to the lymph nodes, where germination occurs. Upon
germination of spores, toxins are produced that lead to flu-like
symptoms and progress to toxemia and death from shock and multi
organ failure [78].
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Anthrax Vaccine Adsorbed and novel vaccines
The current available vaccine is a recombinant protein vaccine
delivered intramuscularly in a 5 regimen dose over the course of 18
months. Following this series, annual boosters are recommended
[80]. The protein is isolated from a toxigenic non-encapsulated form
of the bacterium V770-NPR1 [80-85]. Side effects have been noted in
approximately one-third of vaccinated individuals including: injection
site swelling, redness, and tenderness [86]. The primary component
of this vaccine is PA [83]. Research demonstrates that some
antibodies formed against PA can prevent toxin formation which is a
critical component of vaccine development [87, 88]. For this reason
most research conducted for the formulation of novel B. anthracis
vaccines has utilized PA as a target.
These PA vaccines have been shown to have varying success
upon challenge [3, 4, 80-82, 84, 85, 89-92]. Augmented rPA vaccines
have been combined with CpG ODN, bacterial DNA fragments, E. coli
LPS, complement receptors for targeting APC’s, and complement C3d.
Recombinant PA has been combined with various other B. anthracis
components including inactivated spores, LF and or EF, capsule
gamma DPGA, and unencapsulated spores. Some protection was
shown from PA DNA vaccination but not against fully virulent strains
unless combined with other agents [89]. Recently, a study evaluating
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an IM EP mediated PA DNA vaccine was published. Their results
demonstrated the value of this technology, by achieving survival in 4
of 5 NHP’s against an aerosol challenge of B. anthracis [93].

Hepatitis B Virus
HBV is a member of the Hepadnaviradea family whose
genome is made up of circular DNA. As its name suggests, this family
of viruses causes infections of the liver. Liver disease from HBV can
present in a variety of ways from fulminant hepatitis, cirrhosis, or
hepatocellular carcinoma. Approximately 15-40% of chronic HBV
sufferers will develop significant liver disease.

The main components

of this virus are: surface and core antigens, DNA polymerase, and an x
antigen of unknown function [94]. There are 8 known genotypes of
HBV denoted A through H [95].
The current vaccine for HBV is a recombinant protein vaccine
derived in yeast. The protein used in this vaccine is recombinant
HBsAg. This vaccine is a 3 course vaccine given to infants within the
first two months after birth. Current data shows that vaccination with
this vaccine lasts long term and that additional boosters are not
necessary for properly vaccinated immunocompetent individuals [96].
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For this reason, it is an appropriate candidate for comparison of our
vaccine model. Established protective levels of anti-HBs titers are
greater than 10mIU/ml.

Significance
The development of vaccines has been hampered by the
emergence of infectious agents and lack of new techniques. Novel
methods like DNA vaccination provide a useful alternative to traditional
methods by providing ease of production, stability in transport, small
amounts necessary. Unfortunately, DNA vaccines delivered directly
have been ineffective and require the use of alternate delivery
techniques. EP has been shown to effectively increase gene
expression as well as humoral and CMI with DNA vaccination. Our
model for DNA vaccination involves the use of a novel NPE, the MEA,
for the induction of humoral immunity. This electrode lays flat on the
skin’s surface and is applied after intradermal injection. This method
is far less invasive and is more “friendly” for the patient.
Additionally, when evaluating novel methods of DNA vaccination
it is important to evaluate clinically relevant infectious models to
determine the viability of your method. B. anthracis is the causative
agent of anthrax and a potential threat for use as a bioweapon.
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Finally, quite often when evaluating new methods appropriate
animal models are sometimes not used and fail to appropriately
determine what the possible effect will be in humans. We have utilized
the guinea pig model to more accurately reflect the effect of the MEA
on human skin. This study is significant because it not only
demonstrates a novel method for DNA vaccination but also evaluates
the effectiveness of this method for immunogenicity as well as
translation to the clinic.
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Goals and Objectives

Purpose
The purpose of this study was to assess the functionality of the
MEA for use in DNA vaccination. In particular for the development of
humoral immunity against the clinically relevant BA infectious model in
mice as well as translational relevance by vaccination in a human like
skin model. This study evaluates the effects of both plasmid and EP
has on generation of humoral immunity as well as the effect of EP with
the MEA on the skin.

Hypothesis
Electrically mediated DNA vaccination with the MEA will enhance
immune stimulation against BAs in a mouse model and HBV in a
human-like skin model, guinea pigs.
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Specific Aims
Aim 1: Determine the effect of electrically mediated delivery with the
Multi-Electrode Array on plasmid expression in mouse skin
a. Compare gene expression from electroporation with the MultiElectrode Array at various field strengths to the optimized
skin (4PE) and muscle (4 needle) electrodes.
b. Evaluate the tissue damage and inflammation caused by MEA
mediated electroporation by histology and visual assessment.
c. Evaluate differences in the gene expression profile from MEA
mediated EP at high and low electric fields.

Aim 2: Determine the effect of electrically mediated delivery with the
MEA on immune stimulation against B. anthracis
Sub aim a: Purification of PA plasmid and confirmation of
expression in vitro.
1. Plasmid purification and digestion
2. PA expression in vitro
3. MEA mediated DNA vaccination with PA plasmids
induces anti-PA antibodies in vivo
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Sub aim b: Determine the appropriate delivery conditions for
induction of humoral immunity against B. anthracis.
1. Evaluate the effect of plasmid dose on MEA mediated
humoral immune stimulation
2. Evaluate the effect of number of treatments on MEA
mediated humoral immune stimulation
3. Evaluate the electric field effect of MEA mediated humoral
immune stimulation
Sub aim c: Determine the in vitro protective potential of the
optimized delivery conditions
Aim 3: Evaluate the potential for translation of electrically mediated
delivery with the MEA in a human-like skin model.
a. Evaluate the effect of MEA mediated EP on human-like skin by
histological analysis and visual assessment
b. Evaluate MEA mediated DNA vaccine expression in a humanlike skin model.
c. Determine the humoral stimulation from MEA mediated DNA
vaccination against HBV
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Materials and Methods
General Methods
Plasmid purification. Plasmid DNA was produced by transformation
into E. Coli XL-10 gold cells.

Transformed cells were plated on

antibiotic resistant LB agar (Ampicillin 100ug/ml or Kanamycin
50ug/ml) and incubated overnight at 37°C. Colonies were picked and
cultured in 2.5 Liters of antibiotic containing media. Plasmid was
isolated using Qiagen plasmid Giga-prep kit per manufacturer’s
protocol. Briefly, cultures were spun down at 3000 rpm for 30 minutes
at 4°C. The bacterial pellet was resuspended in 125 ml of Buffer P1.
125mls of Buffer P2 was added and inverted 5 times to mix and
incubated for 5 minutes at room temperature. 125mls of Buffer P3
was added and mixture was added to the Qiafilter and allowed to
incubate for 10 minutes. Mixture was vacuum filtered and 30mls of
Buffer ER was added and incubated on ice for 30 minutes. Qiatip 1000
was equilibrated with 75mls Buffer QBT. Mixture was added to Qiatip
to bind DNA. Tip was washed with 600mls Buffer QC. DNA was eluted
with 100mls of Buffer QT. DNA precipitation was performed with
70mls of isopropanol and spun at 15000 x g for 30 minutes at 4°C.
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DNA pellet was washed with 70% Ethanol and respun for 10 minutes.
Pellet was air dried and resuspended at 2mg/ml in physiological saline.

Cell Lines and Complete Growth Medium: B16F10 cells were
purchased from ATCC and grown in McCoy's 5A media supplemented
with 10% FBS and Gentamycin. J774A.1 Macrophages were also
purchased from ATCC and were grown in DMEM supplemented with
5% FBS, 10mM HEPES Buffer, and Pen-Strep.

DNA Digestion: PA plasmids were digested with restriction enzymes
NotI or KpnI and incubated at 37°C for 1.5 hours. 6X loading dye was
added to stop the digestion and run on a 1% agarose gel with HindIII
lambda marker. The gel was run at 100V for 1 hour. The gel was
incubated for 15 minutes in Ethidium Bromide and UV light used to
visualize the resulting bands.

Mouse model methods
Ethics Statement: Animal procedures were conducted at either USF
vivarium, which is fully accredited by the Association for the
Assessment and Accreditation of Laboratory Animal Care (AAALAC)
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and the Public Health Service (PHS), or Old Dominion University
Center for Bioelectrics' vivarium, which is currently undergoing
AAALAC accreditation. Research was conducted under protocols
approved by the Institutional Animal Care and Use Committee (IACUC)
at both institutions (protocol # 10-006). All animals were housed,
handled and utilized following guidelines of the United States National
Institutes of Health.

Animals and injections: 6-8 week old female Balb/c mice were
intradermally injected at two sites on the left flank with 50µl of
plasmid for experimental animals. Experimental mice were boosted
either once or twice 14 days after the previous treatment (Day 14,
Day 28). All experiments included control animals of 10µg muscle
injected recombinant protein as well as injection only. Recombinant
protein injections were administered at Day 0, 14, and 28. Mice were
bled by tail vein at various time-points.

All animals were

anesthetized with 2-3% isoflurane + O2 for treatments.

Plasmids: The plasmids used for these experiments were pSecTagPA
and pCMVER/PA at various concentrations for B. anthracis studies.
The PA plasmids were generously donated by the Hahn lab (University
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of Hoenheim, Germany). Reporter assays were done using pGwizLuc
and pGwizGFP (Aldevron) also at 2mg/ml.
Electroporation: The MEA was used at applied electric fields ranging
from 25 to 225V/cm but always maintained constant pulse duration
and delay of 150ms. A sequence of 9 4X4 squares was applied 4
times for a total of 72 pulses. Electrodes were circular, gold plated
and flat at the end with a 0.2mm diameter.

In vivo Bioluminescent Imaging: The Caliper life sciences IVIS
Spectrum was used for live animal bioluminescent imaging. Animals
were injected i.p with 15mg/ml luciferin. 20 minutes post luciferin
injection the animals were imaged and relative light units measured.
All luciferase data is represented as average total flux
(photons/sec/sec) per injection site.

Tissue Collection and sectioning: Mouse skin was collected at
various time points from 24-72 hours and up to 7 days after
treatment. Mice were humanely euthanized using CO2 asphyxiation.
Tissue was marked at time of treatment to notate the region to be
removed. Skin samples were immediately placed on dry ice or in
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formalin for sectioning. Frozen skin sections were sliced using the
Thermo Fisher cryostat 550 at -17C in OCT medium

Immunohistochemistry: Sections were placed on slides and fixed
for twenty minutes in 75% Acetone and 25% Methanol and placed at 80°C until imaging. Slides were blocked for 1 hour in PBS with10%
goat serum at room temperature in the dark. FITC conjugated goat
anti-GFP antibody diluted 1:500 in blocking buffer was added
overnight at 4°C. Slides were washed with PBS and Dapi added to
visualize nuclei. Slides were imaged immediately to prevent loss of
fluorescence.

Histology: Skin samples were taken from both mice for histological
analysis. Mouse skin was collected 48 hours after treatment and fixed
in formalin. H & E staining was performed to assess inflammation and
damage.

Sandwich ELISA for PA detection: Anti-PA coating antibody (Abcam
18725) was diluted 5µg/ml in 50mM Sodium Carbonate. 100ul of
coating buffer was added to each well and incubated overnight at 4°C.
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The next day the plate was blocked with PBST + BSA for 2 hours at
37°C. Supernatants were added directly to each well with 100µl,
lysates were lysed with NP40 buffer (100ml of 100mM Trizma pH 8.0,
50ml Glycerol, 5ml Triton X100, 4g NaCl, 10ml of 100mM EDTA pH
7.4, diH2O) for 30 minutes on ice. PA antigen (List Biologicals 171B)
was used as a control to quantitate amount of PA present.

PA was

diluted to 10000ng/ml and 100µl added to each well for standards.
Four fold dilutions were made to generate a standard curve. Samples
were incubated for 2 hours at 37°C. Wells were washed with PBST 5
times. Secondary was (Abcam 18723) added for 1 hour at room
temperature. Secondary was diluted to 1ug/ml and 50ul added to
each well. AP conjugated antibody was added for 1hr in dark at room
temperature. To colorize, pNPP (Sigma) was added and the plate was
read at 405nm.

Indirect ELISA for the determination of antibodies: Briefly,
antigen was coated at 0.1 to 1µg/well and incubated overnight at 4°C.
Plates were blocked with either BSA-PBST (anti-HBs) or 5% skim milk
buffer (anti-PA) for 2 hours at 37°C. Samples were diluted in blocking
buffer and incubated for 1 hour at 37°C. HRP conjugated secondary
antibodies (Santa Cruz) were diluted in blocking buffer to working
concentration and added for 30 to 60 minutes in the dark. R&D
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substrate was added for 10 minutes and stopped with 2N H2SO4.
Plates were read at 450nm and results represented as mean titers.

Toxin neutralization assay: 50,000 cells/well of J774A.1 murine
macrophages were plated in 96 well cell culture plates. The next day
serum was diluted starting at 1:50 in media and incubated for one
hour with 100ng/ml protective antigen. Lethal Factor was added to
the Serum/Protective antigen mix at a final concentration of 80ng/ml.
Media was removed from the cells and the serum/PA/LF mix was
added to the macrophages for 4 hours at 37 and 5% CO2. All plates
contained a titration curve to confirm that the concentration of toxin
used was sufficient to cause 95% cell death. Following the 4 hour
incubation, 25µl of MTT (5mg/ml) was added and incubated for an
additional 2 hours. Media was removed by vacuum suction and 100µl
of DMSO was added to break up crystal formation. Plate was read at
560nm.

Guinea Pig model methods
Ethics Statement: All animal procedures were conducted the
University of South Florida, College of Medicine vivarium which is fully
accredited by AAALAC and the PHS. Research was conducted under a
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protocol approved by the IACUC at the University of South Florida,
College of Medicine (protocol # 2879). All animals were housed,
handled and utilizing following guidelines of the United States National
Institutes of Health.

Animals: Female Hartley guinea pigs between 200-250g were used in
this study to evaluate skin EP conditions. Guinea pigs were housed at
the University of South Florida, College of Medicine vivarium and were
rested for one week prior to experimentation. Guinea pigs were
anesthetized with 2.5-3.0% isoflurane before and during all
procedures. No previous exposure to HBV was known.

Plasmid: The plasmid used in this study was gWiz™ HBsAg
(Aldevron, Fargo, ND). This plasmid encodes for the surface antigen
of Hepatitis B and is driven by the CMV promoter.

Immunization: All guinea pigs were intradermally injected with
100µg (2mg/ml) of gWiz™ HBsAg at two sites on the left flank. MEA
EP was performed at 300V/cm and 150ms and 72 pulses. The two
groups used in this study were control group injection of plasmid only
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(IO) and injection of plasmid plus EP (I +EP). All groups were boosted
with the same condition at Day 14.

Serum collection: Guinea pigs were anesthetized with 2.5-3.0%
isoflurane. Blood was collected from the jugular vein at various time
points from Day 0 through Day 168. Blood was collected and serum
isolated in serum separator tubes. Serum was diluted two-fold
starting at 1:10.

Tissue collection: Guinea pigs were treated as described with
gWiz™ HBsAg with and without EP. Those guinea pigs whose tissue
was collected for plasmid expression were sacrificed 48 hours after one
treatment and skin samples were harvested by excising the treatment
site and followed by freeing. Those guinea pigs whose tissue was
collected to assess damage and cell infiltrate were treated and
harvested 96 hours after one treatment and the tissue was snap
frozen.

Indirect ELISA for the detection of Hepatitis B surface antigen
antibodies: An ELISA was used to assess the production of antibodies
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from treatment and performed per manufacturer’s protocol (Aldevron).
Briefly, a 96-well plate (Nunc) was coated with 10µg/ml of HBsAg
(Aldevron) and allowed to coat overnight at 4°C. The plate was
blocked with 3% BSA in PBST for 2 hours at 37°C. Serum samples
were two-fold diluted in blocking buffer and added to the plate for 2
hours at 37°C. Goat anti-Guinea pig-AP antibody was added at a
1:10000 dilution in blocking buffer. AP substrate, pNPP, (Sigma) was
added to colorize and the plate was read at 405nm.

Immunohistochemistry: An anti-HBsAg was used to detect plasmid
expression. Skin samples taken 48 hours after treatment were frozen,
sectioned, and placed on slides. Slides were rehydrated and then
blocked with 3% BSA in PBST and incubated in a humidifying chamber
for 1 hr. A HRP conjugated anti-HBsAg (AbD Serotec) was made in
blocking buffer at a 1:200 dilution. All samples were counterstained
with H & E.

Histology: Samples collected at 96 hours frozen, sectioned, and
placed on slides were stained with H & E to determine the extent of
cellular infiltrate/inflammation.
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Statistical analysis: All Guinea pigs were bled at Day 0 to determine
background optical density (OD). OD’s were averaged and 2 standard
deviations added to determine positive (0.1 OD). Experimental serum
samples were diluted two-fold starting at 1:10. End point titers were
calculated and plotted as Geometric Means. Significance was
determined by student t-test using the bonferroni correction for
multiple comparisons.
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Results
Aim 1: Determine the effect of electrically mediated delivery
with the MEA on plasmid expression in mouse skin.
Introduction:
EP has been demonstrated to be an effective delivery platform
for DNA. However, it is limited in its use due to the current electrode
designs. Currently those electrodes require either high voltages that
would not be tolerable for human use or PE’s that involve insertion into
the tissue. We have designed a novel electrode that both eliminates
penetration of the electrode as well as reduces the absolute voltage
necessary for delivery. Here we establish that this devices elicits
similar gene expression levels as the current devices with minimal to
no damage.
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a. Comparison of gene expression from EP with the MEA at
various field strengths to the optimized skin (4PE) and
muscle (4 needle) electrodes.
In order to assess the ability of the MEA to enhance gene
expression in a mouse model, Balb/c mice were injected with 50ul of
GwizLuc (2mg/ml) intradermally on the left flank. Sites were
electroporated with various electric fields with the MEA or 100V/cm
with the 4PE. A control group of injection of plasmid only was included

Figure 3. Luciferase Gene expression from MEA EP.
GwizLuc plasmid (2mg/ml) was injected into the left
flank of Balb/c mice. Treatment sites were either EP with
the MEA or 4PE at specified electric fields. Control group
of IO was also included.
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(IO). Figure 3 shows that using the MEA, luciferase expression can be
increased and that the increase is field dependent. Higher electric
fields result in increased luciferase expression. However, all MEA
conditions are greater than IO and demonstrate similar expression
patterns as the control 4PE animals over time. Visual tissue damage
was seen in animals treated with the MEA at 200V/cm. Though this
condition represented the highest level of gene expression with the
MEA conditions above 175V/cm will not be used to prevent potential
tissue damage.
b. Evaluate tissue damage and inflammation caused by MEA
mediated EP by histology and visual assessment.

A

B

C

Figure 4. Effect of MEA mediated EP on mouse skin
histology. Balb/c mice were injected with plasmid DNA and EP
to assess changes in skin from treatment. Samples were
collected 48 hours after treatment. A) No treatment. B) IO of
plasmid DNA. C) Injection and EP with the MEA at 175V/cm.
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Histology was performed to evaluate the skin tissue for damage
at 175V/cm. IO samples show no gross visual difference in swelling or
skin damage from EP treated animals. Histologically, however, (figure
4 a & b) EP samples showed a large influx of cellular infiltrate
c. Evaluate the differences in DNA uptake from MEA mediated
EP at high and low electric fields
Expression of plasmid DNA at high and low electric fields was
evaluated using GFP. The use of GFP instead of Luciferase allows us to
visualize the location and number of cells expressing the protein as
opposed to total expression. Here we were able to evaluate whether
these electric fields have different DNA distribution after EP and
subsequent differences in expression. Figure 5, shows MEA EP at
125V/cm and MEA EP 175V/cm for both 24 and 48 hours after EP.
Enhanced expression from EP can be seen in both 125 and 175V/cm
conditions at different time points. EP with 125V/cm demonstrates the
highest quality expression. EP with 125V/cm has good distribution of
expression along the epidermis and is more pronounced at 48 hours.
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24 Hours

48 Hours

No Tx

A

B

C

D

E

F

125V/cm

175V/cm

Figure 5. GFP expression from MEA mediated EP at
various conditions. Mice were injected with pGwizGFP
plasmid (C-E) and EP at either 125V/cm (C and D) or
175V/cm (E and F). Skin was collected and snap frozen at
24 ( A, C, and E) and 48 (B, D, and F) hours after
treatment.
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Aim 2: Determine the effect of electrically mediated delivery
with the MEA on immune stimulation against B. anthracis.
Introduction
B. anthracis is of clinical relevance as a bioterrorism weapon.
The current available vaccine has several side effects that range from
mild to severe and requires several initial vaccinations followed by
annual boosters. The vaccine is a recombinant protein vaccine and
therefore a good candidate for development of a new vaccine model.
Our group, and others, proposed the use of DNA vaccines to generate
lasting immunity against this threat. In 2004, the Hahn group
constructed two plasmids expressing full length PA. These plasmids
were designed to secrete PA (pSecTagPA; Fig 6A) and bind to the
membrane (pCMVER/PA; Fig 6B).
Their results demonstrated that these plasmids when delivered
by the gene gun could generate humoral immunity including antibodies
against neutralizing epitopes of PA. Here we utilize these established
plasmids to determine whether EP with the MEA can generate humoral
and neutralizing immunity against B. anthracis and those conditions of
the MEA that are best suited for developing immunity.
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A

B

Figure 6 Protective antigen plasmid constructs. Construction of
the PA plasmids used in this study was done by the Hahn lab and
published in 2004 in Vaccine. Both plasmid backbones were
commercially made by Invitrogen and are designed to express full
length PA under control of the CMV promoter A) pCMVER/PA contains
a sequence for targeting expression to the endoplasmic reticulum.
B) pSecTagPA contains a secretion sequence.
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Sub aim a: Confirmation of expression of PA plasmids in
vitro and in vivo
1. PA plasmid preparation and isolation
PA plasmids were prepared as described in Methods and digested
with NotI (pCMVER/PA) and KpnI (pSecTagPA). The resulting digests,
shown in figure 7, show undigested and digested plasmid. Lane 1 is
the HindIII lambda marker. Lanes 2 and 3 are undigested and
digested pCMVER/PA respectively. Lanes 4 and 5 are undigested and
digested pSecTagPA respectively. The bands for pCMVER/PA are seen
at 7230bp corresponding to a correctly linearized plasmid. The band
for pSecTagPA corresponds to 7299bp, again a correctly linearized
plasmid. Both plasmids were purified cleanly and linearize
appropriately and can be used for further work.
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23130/9415
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4361
2322
2027

Figure 7.Isolation and Purification of PA
plasmids.PA plasmids were isolated and prepped
using the Giga prep kit from Qiagen. Once
isolated plasmids were confirmed by DNA
digestion. Lane 1 is the HindIII lambda marker.
Lane 3 is NotI digested pCMVER/PA. Lane 2 is
undigested. Lane 5 is KpnI digested pSecTagPA.
Lane 4 is undigested.
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2. Expression of PA plasmids in vitro
PA plasmids were transfected into B16 F10 mouse melanoma
cells in vitro to confirm that PA was being expressed by the plasmids.
B16 F10 cells were selected because our lab had generated standard
protocols for transfecting this type of cells. Since the goal of this
experiment was to confirm that the plasmids expressed PA, the cell
type used was not critical as long as they were susceptible to
transfection and were not killed by expression of the protein. Cells
were transfected and supernatants and lysates collected after 48
hours. The results in figure 8 demonstrate that the secreting plasmid
has more PA expressed in the supernatant as compared to the
endoplasmic reticulum targeted plasmid. While there is more PA
expressed from the ER plasmid, most of the protein is found within the
lysate. The relatively even expression of PA between the lysate and
supernatant in the secreted plasmids reflects a two fold increase in
secretion as compared to the ER plasmid. Total expression is about
the same between the two plasmids with the secreted plasmid
producing about 10000pg/ml and the ER plasmid producing about
11500pg/ml.
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pCMVER/PA SN
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Figure 8. In vitro expression of PA plasmids in B16
F10 cells. Both PA plasmids were transfected into B16
F10 cells and supernatant and lysates were collected
after 72 hours. Sandwich ELISA was performed to
quantitate expression of PA. rPA was used as a standard
for quantitation.
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3. PA plasmids in vivo.
PA plasmids were injected into the left flank of Balb/c mice and
electroporated with the MEA at 225V/cm. Each plasmid was injected
individually and at a 1:1 combination to determine the amount of
antibody produced by each and together. Shown in figure 9, the
highest level of antibody production was seen with vaccination with the

1.00E+004
pCMVER/PA
pSecTagPA
1:1 Both

#
#

End point titers

1.00E+003

1.00E+002

#

1.00E+001

1.00E+000
3

5

7

9
Weeks

12

Figure 9. In vivo Injection of PA plasmids for the
development of anti-PA antibodies. PA plasmids were
injected into the left flank as described in Methods and EP at
225V/cm with either PA plasmids individually or at a 1:1
combination. #= value is zero
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pCMVER/PA plasmid; however, antibodies were not seen until 6 weeks
after initial vaccination. Vaccination with pSecTagPA produced
antibodies as early as 3 weeks after treatment. Whereas vaccination
with the 1:1 combination resulted in both an early response and
demonstrated similar (even slightly increased) antibody levels as
compared to pCMVER/PA. Based on these results, the 1:1 combination
was selected for use in all future experiments.
EP with the MEA was compared to other EP devices to determine
the effectiveness of antibody production with this electrode. The 4PE
was used as an alternative skin electrode for comparison of skin EP
and the 4 needle was used to facilitate comparison to muscle EP. DNA
was injected into the left flank for skin EP as described in methods.
Muscle groups were injected into the gastrocnemius and the electrode
inserted into the muscle around the injection site and EP administered.
Figure 10, shows that at early timepoints IO animals have higher
expression than muscle injected groups demonstrating the benefit of
using skin as the delivery location. Also at week 3 EP, regardless of
electrode type, increases antibody production as compared to IO but
are not different from each other.

MEA EP samples increase steadily

over time whereas muscle EP animals peak by week 9 and begin to
drop off by week 12. Additionally, when comparing MEA skin delivered
groups to 4PE skin delivered groups there is a noticeable difference in
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antibody production. It is important to note, that even with lower
levels of expression, Figure 3, the MEA can produce equal or slightly
greater antibody production compared to the 4PE.
Skin IO

1.00E+005

MIO
ME+ 100V/cm
4PE 100V/cm
MEA 175V/cm

End point titers

1.00E+004

1.00E+003

#

1.00E+002

1.00E+001

1.00E+000
3

6

9

12

Weeks

Figure 10. Comparison of MEA mediated in vivo delivery
with other EP devices for antibody production. PA plasmids
were combined 1:1 and injected into Balb/c mice. MEA and 4PE
delivered plasmids were injected i.d., whereas 4 needle delivered
plasmid was injected into the gastrocnemius. Serum was
collected over time by tail vein bleed. IO= Injection only; MIO=
Muscle Injection only; ME+ 100V/cm= Muscle + Electroporation at
100V/cm; 4PE 100V/cm= four plate electrode at 100V/cm; MEA
175V/cm= Multielectrode array at 175V/cm. #= value is zero.
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Sub Aim b: Optimization of delivery parameters for DNA

vaccination

with the MEA against Bacillus anthracis
Introduction
Current experiments testing for vaccines against PA include
recombinant protein, spore, and DNA constructs. Most of these
vaccines are derived from the PA protein of B. anthracis because
antibodies against this protein have been shown to have neutralizing
toxin properties. However, several groups are also evaluating spore
proteins either by DNA delivery, recombinant protein or inactivated
whole spores. These vaccines have been shown to have some efficacy
but are not capable of generating responses against toxin components.
The DNA based vaccines, have tested both toxin and spore
components. Two groups have tested the efficacy of muscle EP
delivery of PA DNA. Their results demonstrated that this method can
be used to generate total and neutralizing antibodies. As previously
stated our goal is to use non-invasive EP, namely the MEA, to generate
these responses. However, the EP and DNA delivery conditions cannot
be assumed to be the same as in muscle delivery. Here we assess the
appropriate delivery conditions for i.d. DNA vaccination against B.
anthracis with the MEA. The three parameters tested were: plasmid
dose, number of treatments, and electric field.
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1. Identification of plasmid dose necessary for optimal
DNA vaccination against B. anthracis.
Plasmid DNA was injected into the left flank of Balb/c mice in
various amounts from 100-300ug. EP with the MEA at 225V/cm was
used for all plasmid doses. IO was delivered at 200ug. Antibody
responses were measured by ELISA. The results, Figure 11, show very
little differences in antibody production. There was no detectable
response from IO animals at weeks 3 and 6.

All conditions are

increased above IO at all time points. However, at early timepoints
200µg seems to be slightly increased over 100µg and 300µg. By week
9, 300µg had surpassed 200µg and maintained at week 12. These
results do not generate any significant benefit to increasing plasmid
dose. The largest differences affected by plasmid dose occurred at
weeks 3-6. Over this time 200µg of plasmid shows the largest
differences between groups. For this reason, we have selected to
continue further experimentation with that dose.
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End point titers

#

#

Figure 11. Effect of Plasmid dosing on generation of
antibodies from MEA mediated delivery. Plasmid DNA
ranging from 100 to 300ug was injected into the flank of Balb/c
mice and EP with the MEA at 225V/cm. Serum was collected
over time by tail vein bleed. #= value is zero.
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2. Identification of the number of treatments necessary for
optimal DNA vaccination against B. anthracis.
Animals were treated on either Day 0 and 14 or Day 0, 14, and
28. Antibodies were measured and plotted over time. The results,
Figure 12, again show very little differences in antibody production.
All groups increase over time and are increased over IO. However, by
week 12 the group receiving the third treatment has begun to drop off,
whereas the two treatment group is still increasing. This data
demonstrates that there is not an additional benefit gained from a
third treatment. All further experiments were conducted with a two
treatment protocol at Days 0 and 14.

58

End point titers

#

Figure 12. Evaluation of number of treatments for
generating MEA mediated antibody responses. Plasmids
were injected at Day 0 and 14 or Day 0, 14, and 28. Each
treatment was immediately followed by EP at 175V/cm. Serum
was collected over time by tail vein bleed. #= value is zero.
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3. Identification of the electric field necessary for optimal
DNA vaccination against B. anthracis.
Mice were injected with PA plasmid DNA and followed
immediately with EP at electric fields from 25 to 175V/cm. Serum was
collected and antibodies measured over time. Results, Figure 13,
show that electric field does significantly affect antibody production.
Statistical significance was determined using ANOVA with the TukeyKramer multiple comparisons test. Electric fields below 125V/cm
generate significantly less antibodies than 125 (weeks 9 and 12) and
175V/cm (week 12). Both 125 and 175V/cm are significantly
increased over IO at weeks 9 and 12. While not significantly different
from each other, 125V/cm does induce slightly higher antibody
responses than 175V/cm at all time points from 3-12 weeks.
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Figure 13. Evaluation of electric field from MEA mediated
EP of PA plasmids for the generation of antibodies. PA
plasmids were injected into Balb/b/c mice and EP with the MEA at
fields ranging from 25 to 175V/cm. Serum was collected over
time by tail vein bleed. Statistical analysis was performed using
ANOVA and the Tukey-Kramer multiple comparisons test.
*=p<0.05 compared to IO; += p<0.05 compared to all lower EP
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16

Sub aim c: Vaccine potential of the MEA against B. anthracis
The critical question is whether a protective immune response
can be generated using this delivery method. To assess this, a toxin
neutralization assay was performed to determine the titer of
neutralizing antibodies generated from our “optimized” delivery
conditions. MEA EP conditions for both 125 and 175V/cm were tested
as both conditions generated significantly increased antibody
responses as compared to lower conditions and IO (Figure13). Table 5
shows that 3 out of 5 mice could generate neutralizing antibodies
using the MEA at 175V/cm and 2 out of 5 for 125V/cm. IO and EP
only groups did not have any neutralizing activity.
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Table 5. In vitro protection by Toxin Neutralization Assay.
Condition

Peak serum

Serum

# of mice with

titer

Dilution

TNA’s

pPA IO

3200

50

0 of 5

Backbone + EP

0

50

0 of 5

pPA + EP 175V/cm

12800

50

3 of 5

pPA +EP 125V/cm

25600

50

2 of 5

rPA 10µg i.m.

50000

50

5 of 5

175V/cm

*Serum was diluted 1:50 and combined with PA to prevent toxin
formation. Peak serum titers are expressed as total average end
point titers for each condition.
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Aim 3: Evaluate the potential for translation of electrically
mediated delivery with the MEA in a human-like skin model. 1
Introduction
This is the beginning text of the section containing previously
published information [97]. Utilizing the B. anthracis model allowed us
to evaluate this approach for DNA vaccine delivery in a clinically
relevant infectious disease model, it also needs to be understood that
the approach and particularly the electrode array had not as yet been
tested in humans. Therefore, it was also important for us to evaluate
the development of immunity and assess the condition of the skin from
treatment with the MEA in a human like skin model. The best small
animal model for human skin is the guinea pig. Their skin is
approximately the same thickness (about 1mm) and contains similar
properties for antigen presenting cells [63]. Hairless guinea pigs are
the best model because while they still have hair follicles they do not
possess the fur that normal guinea pigs do, however due to an
infection in the hairless guinea pig population it was not feasible to use

1

Portions of these results have been previously published (Donate, A et al 2011 [97]) and are utilized
without need for publisher permissions due to the Creative Commons License. Legal Code is included in
Supplementary Materials. Level of work contributed by Authors: Amy Donate 70%, Yolmari Cruz 5%,
Domenico Coppola M.D. 5%, and Richard Heller Ph.D. 20%.
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this model for vaccination testing. Therefore, we used regular guinea
pigs and their hair was shaved.
Our initial experiments with this guinea pig model were to
evaluate expression at various EP conditions with the MEA and to
compare those to our current 4PE skin electrode. Our results
published in Human Gene Therapy in 2010 demonstrated that the MEA
was an efficient delivery electrode for gene expression in the guinea
pig. Luciferase expression equivalent to the 4PE could be achieved as
low as 250 to 300V/cm and 150ms. Additionally, we could increase
gene expression by increasing the area of skin EP [65]. MEA EP with
GFP plasmid showed that this expression was localized to the
epidermal and dermal layers of the skin. These results make the MEA
a good candidate for vaccination in our human like skin model.
a. Plasmid expression from EP.
The first step in
evaluating the MEA for delivery
of DNA vaccines in a humanlike model was to evaluate
expression of gWiz™ HBsAg,
Figure 14. Guinea pigs

Figure 14. Gwiz™HBsAg plasmid.
Map image from aldevron.com
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were treated as described in Methods with or without EP using the MEA
at 300V/cm. Guinea pigs were humanely euthanized 48 hours after
delivery and the treated skin harvested and snap frozen. Expression
of HBsAg was determined by immunohistochemistry.
In Figure 15 A and B, expression of HBsAg is seen in IO and MEA
EP samples. Increased staining compared to IO samples can be
observed in the MEA EP samples. Expression of HBsAg is seen within
the epidermis of both groups, but is in much higher quantity in the
MEA EP group. Additionally, deeper expression into the dermis is also
noted in the MEA EP condition. It should also be noted that there is a
slight separation of the epidermis in the MEA EP group. This damage
was evaluated in further experimentation and found to be minimal and
completely recoverable over time, Figure 16.
b. Immune cell infiltrate and tissue damage
Other than expression of plasmid DNA, another important factor
for developing immunity is the recruitment of immune cell infiltrate.
This is an important consideration especially for DNA vaccination
because it can often be a limiting factor for this type of vaccine. To
test for this, skin sections were collected 96 hours after treatment,
frozen, and stained with H & E. Induction of immune cell infiltrate was
observed (Fig 15 C-F 100X magnification). Background levels, Fig
15C, of infiltrate are demonstrated in no treatment control and
66

correspond to low levels of cellular infiltrate (purple). IO samples
show slight increases in infiltrate as compared to no treatment, Fig
15D. In contrast, MEA EP samples show a large increase in cellular
infiltrate, Fig 15E. The substantial influx of immune cells can be seen
more clearly in figure 15F (200x magnification MEA EP).
It is important to observe that edema was noted in all injected
tissues. This is most likely a result of the injection and not of the EP
as it is seen in the IO samples as well. Edema did not appear
increased due to EP. Additionally, in most samples, tissue damage
and necrosis were not seen. However, two EP delivered samples had
minimal ulcerations at 96 hours after treatment, one of which also had
about 1% necrosis. There were no other samples showing damage or
necrosis. This is further evaluated by macroscopic evaluation of the
skin.

Injection site redness is seen immediately after treatment, with

a slight increase in redness in the MEA EP treated sites, Figure 16. By
48 hours after treatment most of the redness has cleared up and IO
and MEA EP groups are indistinguishable from one another. Complete
visual recovery of the skin is seen by Day 7.
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Figure 15. Histological Assessment of Guinea
pig Skin for Expression, Inflammation, and
Damage from MEA Mediated EP. Female guinea
pigs were injected on the left flank with
pGwizHBsAg. Immunohistochemistry was
performed to determine expression of HBsAg after
48 hours A) IO and B) EP 300V/cm. Skin samples
were collected for H & E staining 96 hours after
treatment with the MEA at 300V/cm. C) No tx,
D) IO, E) EP 300V/cm F) EP 300V/cm 200X
magnification.
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Figure 16. Visual assessment of guinea
pig skin for damage and recovery.
Guinea pig skin was imaged immediately
after treatment through Day 7 to determine
damage and healing.
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c. Anti-Hepatitis B surface antigen antibodies
The development of specific immunity is a more accurate
indicator of an effective immune response from treatment. Therefore,
serum was collected from treated guinea pigs and anti-HBs were
measured by ELISA over time. Results, Figure 17, show significant
increases in antibody expression by week 3 and those responses
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Figure 17. Evaluation of the development of humoral
immunity from MEA mediate EP in a human like skin
model. Guinea pigs were injected on the left flank and EP
groups were immediately EP with the MEA at 300V/cm.
Guinea pigs were bled by jugular vein over time and serum
used for ELISA. Both groups had an n-=18 from three
independent experiments. Statistical analysis was performed
using a student t-test and bonferroni correction.
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remain significantly increased through week 24. The results are
represented as GMT with IO groups having a peak GMT of 1000 and
MEA EP at 5000 (Figure 17). The peak fold increase of MEA EP over IO
was 6.5 at week 18. However, the fold increase remained relatively
constant at about 5 for all time points. The titers measured do
correlate with titers conferring protection [22, 41, 51, 119, 120].
Statistical analysis was performed using student t-test and bonferroni
correction to correct for multiple timepoints. Error is represented as
standard error of the means.
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Discussion
The data presented in this dissertation reflect that the MEA can
be an effective mediator of gene expression, inflammation, and
humoral immunity and that those responses are highly dependent on
the electric field used in both mice and guinea pigs. DNA vaccination
is advantageous because it does not integrate into the host DNA, it is
cost effective to produce and easily stored, it can be highly specific for
tissue and/or cell type and can be made to vaccinate against multiple
agents simultaneously. The skin is an ideal target for DNA vaccination
due to the large surface area and presence of antigen presenting cells
like langerhan’s and dermal dendritic cells, specialized for induction of
immunity [98].
However, injection of plasmid alone does not induce high enough
immune responses to be protective. EP is one method that has been
shown to increase both plasmid expression as well as immunity.
Previous EP methods have involved painful penetrating electrodes that
go into the muscle to facilitate delivery. Further advancements have
been made using non-penetrating electrodes such as caliper and plate
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electrodes. However, these electrodes require high voltages to
enhance delivery and therefore can cause tissue damage.
Our initial experiments in mice evaluated the gene expression
from intradermal delivery with either the MEA at various field strengths
or the optimized 4PE at 100Vcm. The data (Figure 3) showed that
while gene expression with the 4PE represented the highest expression
of luciferase the MEA could increase luciferase expression above IO
and that by increasing the electric field could be made similar to the
4PE in mice. MEA EP conditions above 200V/cm were originally tested
but resulted in visual damage of the skin. The goal of this dissertation
was to determine the effectiveness of this method for use in DNA
vaccination; therefore, visual tissue damage is not considered an
acceptable side effect. Therefore only those conditions resulting in no
visual damage were used in the rest of the studies (conditions of
175V/cm or less). Previously published results in rats demonstrated
that at higher electric fields of 250V/cm the MEA could actually result
in higher gene expression than the 4PE [21] and this was later also
demonstrated in guinea pigs [55]. The differences in gene expression
with the MEA and 4PE between these animal models is most likely
related to skin thickness and structure of the two larger rodent
models. Both of these animals have thicker skin than mice and

73

therefore can be more easily injected into the dermis as well as having
a more substantial network of cells for expression.
Upon evaluating the effect of the MEA on damage and
inflammation in mice, we were able to determine that EP with the MEA
did induce inflammation and cellular recruitment when injected with
plasmid DNA. Edema was also seen but it was not isolated to EP
delivered animals and is most likely an injection effect. The cellular
infiltrate seen at 48 hours after treatment is most likely not from a
specific response to antigen. Rather it is an effect from MEA EP. This
is a benefit to using EP as the delivery method for DNA vaccination. It
has previously been shown, and this data supports the idea that EP
has an adjuvant effect.
While overall gene expression is an important factor for
determining electrodes and electric fields another important
consideration is where the plasmid DNA is being expressed. Are there
a large number of cells with a low copy number of plasmid or are there
a few cells with high copy numbers? We proposed to answer this
question by injecting with GFP and looking at GFP expression at 24
and 48 hours after treatment (Figure 5). IO was used as a control and
we evaluated high and low electric fields, based on luciferase
expression, using the MEA. We were able to determine that
expression was low at 24 hours but could be seen in the EP samples
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(both 125 and 175V/cm). However, at 48 hours GFP expression can
be seen in the IO samples. MEA EP with 125v/cm appears to still have
higher expression and that expression is seen throughout the
epidermis and to some extent in the dermis. MEA EP with 175V/cm
showed fewer cells expressing GFP than either IO or MEA EP at
125V/cm and that most of the expression was within the dermis.
Based on the luciferase expression in Figure 3, we show that the total
expression with MEA EP at 175V/cm is approximately two fold higher
than with 150V/cm. It would stand to reason, given the trend of
increasing gene expression with increasing electric field, that 125V/cm
would demonstrate even lower expression levels than 150V/cm. The
difference between these groups may be the number of cells
transfected, Figure 5. When using higher electric fields more cells are
killed during treatment and therefore less cells can be transfected, but
those cells that survive are more greatly “porated” and can allow a
greater amount of DNA into the surviving cells. In the case of the
lower electric field, less DNA can be taken up into the cells but more
cells are moderately porated. This results in a wider spread of DNA
uptake and expression. Increases in cellular infiltrate may also
represent protective effects that are not represented by measurement
of antibody responses and neutralizing activity. Early work conducted
with the gene gun was also suggestive of this effect [99, 100]. In that
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study, toxin neutralization was quite low and in several cases nonexistent; however, several of these animals were protected in lethal
challenge assay. The question remains, which of these conditions is
more important in regards to DNA vaccination? This was the goal in
Aim 2; to evaluate what vaccinations conditions resulted in the highest
levels of humoral immunity.
To evaluate the development of humoral immunity against a
clinically relevant infectious agent we used B. anthracis as a model.
While B. anthracis has a currently available vaccine it is not used for
the general population due to the side effects as well as the heavy
initial inoculation schedule. The goal with development of new
vaccines for B. anthracis is to reduce the production burden, side
effects, and the number of initial inoculations necessary for
vaccination. It also has a well-studied small rodent model in the mice,
as well as highly correlated in vitro assays of protection. We received
two plasmids from Hahn et al to study the development of DNA
vaccination with the MEA. These plasmids expressed the full length PA
protein in commercially available backbones from Invitrogen. These
backbones consisted of either a secretion sequence (pSecTag2B) or a
sequence targeting the endoplasmic reticulum to generate a
membrane bound form of the protein (pCMVER). Once the plasmids
had been purified (Figure 7), we evaluated expression in vitro and in
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vivo. Both plasmids performed as expected. In vitro, expression of PA
from pCMVER/PA was found primarily in the lysate, whereas
expression from pSecTagPA increased expression in supernatant about
two fold. In vivo injection of both plasmids individually resulted in the
development of anti-PA antibodies when delivered by EP with the MEA.
Total antibody production was highest with pCMVER/PA but was not
seen until week 6. Total antibody production from electrically
mediated pSecTagPA was seen at early timepoints but had waned by
week 9 and did not reach as high levels as pCMVER/PA. We combined
the two plasmids in a 1:1 ratio (pPA) to determine if this would
generate a combination of these two responses. The result was both
an early and high antibody response that lasted at least 12 weeks
providing the benefit of both plasmids. This information supported the
stated report by Hahn et al 2004 [99].
How does EP with the MEA compare to other electrode devices
for the development of humoral immunity? Muscle EP has been
demonstrated to induce high levels of humoral immunity due to the
long lasting expression of protein in the muscle. However, it is not
naturally an immune generating system. The skin, however, is an
ideal target for DNA vaccination. We evaluated our 4 needle muscle
electrode, with the MEA, and the 4PE to determine how well the MEA
can induce humoral immunity. Our results generated equal responses
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at early timepoints regardless of electrode used. However, at week 6,
antibodies from skin EP devices had increased slightly above muscle
EP. EP with the 4PE began to decrease by week 9, at which time the
muscle EP peaked above both skin electrodes. EP with the MEA
steadily increased even through week 12 when muscle EP began to
decrease. Three interesting points should be mentioned. First,
differences were seen in the IO groups. Skin IO responses were seen
as early as week 3, whereas muscle took until week 6 to develop. This
supports the immune stimulating idea of using the skin. Second, even
though when the 4PE generated higher luciferase gene expression
compared to the MEA, this was not seen when evaluating antibody
responses which showed that delivery with the MEA generated higher
responses. Therefore, based on these results, the MEA is a superior
electrode as compared to the 4PE for stimulating immune responses.
Finally, EP with the MEA generates similar immune responses as
muscle EP over time and may maintain that immunity over longer
periods of time.
Our initial studies were very promising, so we set out to
determine the optimal delivery parameters for development of
humoral immunity using the MEA. The three parameters we evaluated
were amount of plasmid, treatment course, and electric field. Only
small differences were seen in varying the amount of plasmid, and
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none of these differences were significant. However, we could see
small increases from increasing the amount of plasmid, but we
deemed this irrelevant as injection with 200µg was the highest at
weeks 3 and 6. Similar results were seen with the treatment course,
either a two treatment course at Days 0 or 14 or a three treatment
course at Day 0, 14, and 28 were evaluated. While there were only
small differences seen between these two treatments it did appear
that the three treatment condition started to decrease antibodies
earlier than the two treatments. This may be able to be explained by
plasmid clearance. It was reported that too much plasmid in the skin
can result in faster clearance of the plasmid [101]. If this is the case
then development of humoral immunity could be even more limited by
a decrease in the time of expression from over treatment. As noted in
our other experiments the two treatment course appears to still be
increasing at week 12. Finally, evaluating the effect of electric field on
development of humoral immunity resulted in significant differences.
At all timepoints MEA EP with 125V/cm demonstrated the highest
levels of antibody production. This may be explained by the GFP data
presented earlier in this dissertation where a larger area was
expressing plasmid than in the higher EP conditions. Interestingly,
125V/cm demonstrated significantly increased responses as compared
to all lower conditions at weeks 9 and 12 making it the optimal MEA EP
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condition for the development of humoral immunity against B.
anthracis. However, conditions as high as 175V/cm can be used and
demonstrate significant increases as compared to IO and EP conditions
lower than 125V/cm as well thought 125V/cm is slightly higher they
are not significantly different from one another.
Additionally, when conducting our neutralizing assays, those
animals that did not elicit 50% protection, and were therefore not
considered protected, did still demonstrate some protective effects at
20-40%. This was not seen in the IO or backbone controls where at
least 95% cell killing occurred. Despite not being enough protection to
be considered “protected”, there was some response in every MEA
treated animal at 175 and 125V/cm.
Our results compare favorably to most other published DNA
vaccines in the Balb/c model [99, 102-106]. Those studies reporter
higher total IgG in Balb/c mice required additional boosters, addition of
recombinant protein boosts, [107, 108] or the use of signaling
adjuvants. Studies conducted in other mouse models have shown
antibody responses that exceeded our results [40, 45, 100, 109, 110].
This may be explained by differences in the immunogenicity of the
models. Balb/c mice are not highly susceptible to challenge from nonencapsulated toxigenic strains of B. anthracis, whereas mouse models
like A/J mice are highly susceptible [111]. In one study, that used
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both A/J and Balb/c mice evaluated the development of humoral
immunity against B. anthracis was evaluated. The A/J mice developed
almost a ten-fold higher response than the Balb/c mice [100].
Our results compare favorably to muscle EP as well. Two other
studies, one in mice [45] and one in non-human primates [93], have
been conducted specifically evaluating the use of EP to deliver a B.
anthracis vaccine. Our results are similar to the mouse study
demonstrating approximately 25000 titers and peaking at similar time
points between 6-9 weeks. While our study required additional DNA,
the use of the non-invasive MEA provides a positive advancement to
this study. The NHP experiment was conducted with penetrating
needle electrodes into the muscle. Their results showed the
development of protective immune response [93]. While it would be
difficult to compare our results to these, we feel that their data
corroborate the claim that EP could be an effective delivery method for
DNA vaccination against B. anthracis. We believe our method may be
a way of making this treatment even more tolerable and reducing the
invasiveness.
In aim 3 we evaluated the effect of using the MEA for DNA
vaccination in a human-like skin model. EP with the MEA generated
increased plasmid expression as well as an increase in immune
infiltrate after treatment. The magnitude of immune infiltrate was
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greater in EP groups than IO and there was minimal to no skin damage
associated. Specific, lasting, and significant levels of antibodies were
greater than IO. This is the first report to demonstrate the use of the
MEA for DNA vaccination in a human-like skin model.
As expected from our previous publication [55], EP with the MEA
enhanced expression. While the exact mechanism involved in EP
remains unknown, increased plasmid expression at least in the case of
DNA vaccination, plays an important role in recognition by the immune
system [112]. EP has been shown to have an adjuvant effect by
recruiting immune cells to the site of pulse application [2]. In our
study, we saw an influx of nucleated cells from EP treated samples,
shown in figure 14. These cells are most likely neutrophils and
macrophages based on morphology. This is most likely a combination
of both an EP mediated adjuvant effect and increased plasmid
expression. The induction of macrophages and polymorpho-nucleated
neutrophils is indicative of a chronic inflammatory response. While the
perception of prolonged inflammation is typically negative, in our case
it indicates that the expression of the plasmid is present for a
prolonged period of time, giving the immune response enough time to
perform its function. Based on our earlier work, we would expect this
prolonged expression to decrease after approximately 14 days,
therefore allowing the body to heal and not generate deleterious
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effects from inflammation [1, 55]. As shown in Figure 15, we can see
that any visual effects from EP inflammation have recovered by Day 7.
These findings seem to correlate with our antibody data, where
an increase in the presence of specific antibodies was measured over
time. These antibodies were significantly increased as compared to
injection only. GMT’s ranged from 4000-16000 peaking at week 18.
Antibody levels remained elevated until dropping off after week 21, but
still remained increased as compared to injection only. The enhanced
intensity of humoral immunity by EP with the MEA corresponds to
previously published skin EP results [113-116]. One of the primary
reasons for evaluating our delivery method with HBV was because it is
a well characterized vaccination model. Published studies have
reported geometric mean titers in conjunction with protective efficacy
in guinea pigs. While the presented GMT’s in these papers were higher
than ours, they also reported protective levels more than 100 fold
above the necessary levels of 10mIU/ml. Our GMT’s are likely to still
be within the protective range without generating unnecessary
additional responses [117, 118]. Compared specifically to HBV DNA
vaccines delivered by EP several animal models have been evaluated
and EP has been shown to have protective levels from 10-1000mIU/ml
[22, 41, 51, 119, 120]. The most recent comparable publication
evaluated a minimally invasive device for protective vaccination
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against influenza [120]. While their results were only presented as
neutralizing titers against flu and cannot be compared directly we
believe that our electrode design generates immune responses of
equal quality without tissue penetration.
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Conclusions
In this study we evaluated the use of the MEA for increased gene
expression, inflammation, damage and the induction of humoral
immunity. These criteria were evaluated in two infectious models as
well as two animal models. Our initial results in the mouse
demonstrated that gene expression could be enhanced in mice with
increasing electric fields with the MEA and the highest field that could
be used without visual tissue damage was 175V/cm. Additionally,
differences were seen in GFP expression based on the electric field
applied. Lower electric fields, which correlated to lower total luciferase
expression, showed a slight increase in the number of cells transfected
as compared to higher electric fields (higher total luciferase expression
but less total cells transfected). Inflammation was also noted in the
mouse model as early as 48 hours after injection and EP.
In our mouse model against B. anthracis we were able to
determine that plasmid dose and number of treatments played only a
small role in development of humoral immunity. Of the factors we
studied, the most important was the electric field. Electric fields
ranging from 125-175V/cm showed significant increases in humoral
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immunity as compared to lower and IO conditions. They also
correlated to 40-60% protection in our in vitro toxin neutralization
assay.
Finally, in our guinea pig skin model against HBV we
demonstrated that the MEA would effectively mediate increases in
humoral immunity in the human like skin model. Our results showed
increased gene expression, inflammation, and significant increases in
humoral immunity at all time-points through 6 months as compared to
IO. Slight redness was seen after treatment with the injection and
MEA EP but was not greater than IO after 24 hours and was
completely recovered by Day 7.
In conclusion, using the MEA for EP delivery effectively increases
gene expression, immune cell infiltrates and humoral immunity in both
mice and the human like skin model, guinea pig and therefore should
continued to be utilized for DNA vaccine studies.
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Future Directions
The MEA should continue to be evaluated for use in DNA
vaccination against other clinically relevant infections. There are
several areas that could be studied to more completely evaluate the
effect of MEA mediated EP. First, we evaluated the induction of CMI
since EP has been shown to enhance this type of immunity. Based on
our results showing cellular infiltrate the MEA is likely having an effect
on cell mediate immunity as well. Specifically, induction of CD4+ and
CD8+ T cells should be evaluated.
Secondly, the addition of adjuvants could enhance the immune
response and may provide greater longer lasting protection. Recently,
plasmid based cytokine adjuvants like IL-15, IL-2, and IL-12 have
been used to enhance immunity. The appropriate adjuvant would be
dependent on the infectious model, whether humoral or cell mediated
immunity was important to adjuvant. Alternatively, the use of cell
specific promoters could isolate DNA uptake.

Our studied utilized the

MEA to the skin to theoretically increase DNA uptake by antigen
presenting cells, but using a promoter that would isolate DNA uptake
and gene expression to APC’s or more specifically dendritic cells for
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example would increase antigen presentation and may increase
immunogenicity.
Finally, a benefit of DNA vaccination is that the DNA can be
made to encode for as many or as few components as necessary. In
the case of development of a MEA mediated DNA vaccine against B.
anthracis plasmid addition of spore components with the toxin
component may provide greater protection during an actually
inhalational infection by providing immunity long before toxin
production. Alternatively, more highly optimized plasmids expressing
smaller portions of PA (namely the binding epitope domain IV of PA).
Using only very specific regions of PA would eliminate excess antibody
production to generate only those antibodies that would inhibit toxin
formation and enhance protection.

88

Literature Cited
1.

Guo, S., Donate, A., Basu, G., Lundberg, C., Heller, L., and
Heller, R. (2011) Electro-gene transfer to skin using a
noninvasive multielectrode array. J Control Release 151: 256262.

2.

Abdulhaqq, S. A., and Weiner, D. B. (2008). DNA vaccines:
developing new strategies to enhance immune responses.
Immunol Res 42: 219-232.

3.

Encke, J., zuPutlitz, J., and Wands, J. R. (1999). DNA vaccines.
Intervirology 42: 117-124.

4.

Giese, M. (1998). DNA-antiviral vaccines: new developments and
approaches--a review. Virus Genes 17: 219-232.

5.

Gurunathan, S., Klinman, D. M., and Seder, R. A. (2000). DNA
vaccines: immunology, application, and optimization*. Annu Rev
Immunol 18: 927-974.

6.

Nathanson, N., and Langmuir, A. D. (1963). The Cutter Incident.
Poliomyelitis Following Formaldehyde- Inactivated Poliovirus
Vaccination in the United States during the Spring of 1955. Ii.
Relationship of Poliomyelitis to Cutter Vaccine. Am J Hyg 78: 2960.

7.

Bellet, J. S., and Prose, N. S. (2005). Skin complications of
Bacillus Calmette-Guerin immunization.CurrOpin Infect Dis 18:
97-100.

8.

Wolff, J. A., , Malone RW, Williams P, Chong W, Acsadi G, Jani A,
Felgner PL. (1990). Direct gene transfer into mouse muscle in
vivo. Science 247: 1465-1468.

9.

Ulmer, J. B., Donnelly JJ, Parker SE, Rhodes GH, Felgner PL,
Dwarki VJ, Gromkowski SH, Deck RR, DeWitt CM, Friedman A, et
al. (1993). Heterologous protection against influenza by injection
of DNA encoding a viral protein. Science 259: 1745-1749.
89

10.

Acsadi, G., Jiao SS, Jani A, Duke D, Williams P, Chong W, Wolff
JA.. (1991). Direct gene transfer and expression into rat heart in
vivo. New Biol 3: 71-81.

11.

Davis, H. L., Demeneix, B. A., Quantin, B., Coulombe, J., and
Whalen, R. G. (1993). Plasmid DNA is superior to viral vectors
for direct gene transfer into adult mouse skeletal muscle. Hum
Gene Ther 4: 733-740.

12.

McMahon, J. M., and Wells, D. J. (2004). Electroporation for
gene transfer to skeletal muscles: current status. BioDrugs 18:
155-165.

13.

Coban, C., Koyama, S., Takeshita, F., Akira, S., and Ishii, K. J.
(2008). Molecular and cellular mechanisms of DNA vaccines.
Hum Vaccin 4: 453-456.

14.

Weaver, J. C. (1995). Electroporation theory. Concepts and
mechanisms. Methods MolBiol 55: 3-28.

15.

Neumann, E., Schaefer-Ridder, M., Wang, Y., and Hofschneider,
P. H. (1982). Gene transfer into mouse lyoma cells by
electroporation in high electric fields. EMBO J 1: 841-845.

16.

Nishi, T., Yoshizato K, Yamashiro S, Takeshima H, Sato K,
Hamada K, Kitamura I, Yoshimura T, Saya H, Kuratsu J, Ushio Y.
(1996). High-efficiency in vivo gene transfer using intraarterial
plasmid DNA injection following in vivo electroporation. Cancer
Res 56: 1050-1055.

17.

Heller, R., Jaroszeski M, Atkin A, Moradpour D, Gilbert R, Wands
J, Nicolau C. (1996). In vivo gene electroinjection and
expression in rat liver. FEBS Lett 389: 225-228.

18.

Mathiesen, I. (1999). Electropermeabilization of skeletal muscle
enhances gene transfer in vivo. Gene Ther 6: 508-514.

19.

Mir, L. M., Bureau MF, Gehl J, Rangara R, Rouy D, Caillaud JM,
Delaere P, Branellec D, Schwartz B, Scherman D. (1999). Highefficiency gene transfer into skeletal muscle mediated by electric
pulses. ProcNatlAcadSci U S A 96: 4262-4267.
Aihara, H., and Miyazaki, J. (1998). Gene transfer into muscle by
electroporation in vivo. Nat Biotechnol 16: 867-870.

20.

90

21.

Heller, L. C., and Heller, R. (2006). In vivo electroporation for
gene therapy. Hum Gene Ther 17: 890-897.

22.

Widera, G., Austin M, Rabussay D, Goldbeck C, Barnett SW,
Chen M, Leung L, Otten GR, Thudium K, Selby MJ, Ulmer JB.
(2000). Increased DNA vaccine delivery and immunogenicity by
electroporation in vivo. J Immunol 164: 4635-4640.

23.

Babiuk, S., Baca-Estrada ME, Foldvari M, Storms M, Rabussay D,
Widera G, Babiuk LA. (2002). Electroporation improves the
efficacy of DNA vaccines in large animals. Vaccine 20: 33993408.

24.

Muthumani, K., Lambert VM, Sardesai NY, Kim JJ, Heller R,
Weiner DB, Ugen KE. (2009). Analysis of the potential for HIV-1
Vpr as an anti-cancer agent. Curr HIV Res 7: 144-152.

25.

Otten, G., Schaefer M, Doe B, Liu H, Srivastava I, zur Megede J,
O'Hagan D, Donnelly J, Widera G, Rabussay D, Lewis MG,
Barnett S, Ulmer JB. (2004). Enhancement of DNA vaccine
potency in rhesus macaques by electroporation. Vaccine 22:
2489-2493.

26.

Otten, G. R., Schaefer M, Doe B, Liu H, Megede JZ, Donnelly J,
Rabussay D, Barnett S, Ulmer JB. (2006). Potent
immunogenicity of an HIV-1 gag-pol fusion DNA vaccine
delivered by in vivo electroporation. Vaccine 24: 4503-4509.

27.

Rosati, M., Bergamaschi C, Valentin A, Kulkarni V, Jalah R, Alicea
C, Patel V, von Gegerfelt AS, Montefiori DC, Venzon DJ, Khan
AS, Draghia-Akli R, Van Rompay KK, Felber BK, Pavlakis GN.
(2009). DNA vaccination in rhesus macaques induces potent
immune responses and decreases acute and chronic viremia
after SIVmac251 challenge. ProcNatlAcadSci U S A 106: 1583115836.

28.

Hu, H., Huang, X., Tao, L., Huang, Y., Cui, B. A., and Wang, H.
(2009). Comparative analysis of the immunogenicity of SARSCoV nucleocapsid DNA vaccine administrated with different
routes in mouse model. Vaccine 27: 1758-1763.

91

29.

Lu, B., Tao L, Wang T, Zheng Z, Li B, Chen Z, Huang Y, Hu Q,
Wang H. (2009). Humoral and cellular immune responses
induced by 3a DNA vaccines against severe acute respiratory
syndrome (SARS) or SARS-like coronavirus in mice. Clin Vaccine
Immunol 16: 73-77.

30.

Laddy, D. J., Yan J, Khan AS, Andersen H, Cohn A, Greenhouse
J, Lewis M, Manischewitz J, King LR, Golding H, Draghia-Akli R,
Weiner DB. (2009). Electroporation of synthetic DNA antigens
offers protection in nonhuman primates challenged with highly
pathogenic avian influenza virus. J Virol 83: 4624-4630.

31.

Zheng, L., Wang, F., Yang, Z., Chen, J., Chang, H., and Chen, Z.
(2009). A single immunization with HA DNA vaccine by
electroporation induces early protection against H5N1 avian
influenza virus challenge in mice. BMC Infect Dis 9: 17.

32.

Chen, J., Fang, F., Li, X., Chang, H., and Chen, Z. (2005).
Protection against influenza virus infection in BALB/c mice
immunized with a single dose of neuraminidase-expressing DNAs
by electroporation. Vaccine 23: 4322-4328.

33.

Chen, Z., Kadowaki S, Hagiwara Y, Yoshikawa T, Matsuo K,
Kurata T, Tamura S. (2000). Cross-protection against a lethal
influenza virus infection by DNA vaccine to neuraminidase.
Vaccine 18: 3214-3222.

34.

Bachy, M., Boudet F, Bureau M, Girerd-Chambaz Y, Wils P,
Scherman D, Meric C. (2001). Electric pulses increase the
immunogenicity of an influenza DNA vaccine injected
intramuscularly in the mouse. Vaccine 19: 1688-1693.

35.

Ramanathan, M. P., Kutzler MA, Kuo YC, Yan J, Liu H, Shah V,
Bawa A, Selling B, Sardesai NY, Kim JJ, Weiner DB. (2009).
Coimmunization with an optimized IL15 plasmid adjuvant
enhances humoral immunity via stimulating B cells induced by
genetically engineered DNA vaccines expressing consensus JEV
and WNV E DIII. Vaccine 27: 4370-4380.

36.

Wu, C. J., Lee, S. C., Huang, H. W., and Tao, M. H. (2004). In
vivo electroporation of skeletal muscles increases the efficacy of
Japanese encephalitis virus DNA vaccine. Vaccine 22: 14571464.
92

37.

Zhao, B., Jin, N. Y., Wang, R. L., Zhang, L. S., and Zhang, Y. J.
(2006). Immunization of mice with a DNA vaccine based on
severe acute respiratory syndrome coronavirus spike protein
fragment 1.Viral Immunol 19: 518-524.

38.

Zucchelli, S., Capone S, Fattori E, Folgori A, Di Marco A,
Casimiro D, Simon AJ, Laufer R, La Monica N, Cortese R, Nicosia
A. (2000). Enhancing B- and T-cell immune response to a
hepatitis C virus E2 DNA vaccine by intramuscular electrical gene
transfer.J Virol 74: 11598-11607.

39.

Luxembourg, A., Hannaman, D., Ellefsen, B., Nakamura, G., and
Bernard, R. (2006).Enhancement of immune responses to an
HBV DNA vaccine by electroporation. Vaccine 24: 4490-4493.

40.

Kim, S. H., Park SA, Kim HK, Cho YJ, Kim KS, Kim YH, Chun JH,
Lee NG. (2008). Enhancement of the immune responses of mice
to Bacillus anthracis protective antigen by CIA07 combined with
alum. Arch Pharm Res 31: 1385-1392.

41.

Babiuk, S., Tsang, C., van Drunen Littel-van den Hurk, S.,
Babiuk, L. A., and Griebel, P. J. (2007). A single HBsAg DNA
vaccination in combination with electroporation elicits long-term
antibody responses in sheep. Bioelectrochemistry 70: 269-274.

42.

Best, S. R., Peng S, Juang CM, Hung CF, Hannaman D, Saunders
JR, Wu TC, Pai SI. (2009). Administration of HPV DNA vaccine
via electroporation elicits the strongest CD8+ T cell immune
responses compared to intramuscular injection and intradermal
gene gun delivery. Vaccine 27: 5450-5459.

43.

Seo, S. H., Jin, H. T., Park, S. H., Youn, J. I., and Sung, Y. C.
(2009). Optimal induction of HPV DNA vaccine-induced CD8+ T
cell responses and therapeutic antitumor effect by antigen
engineering and electroporation. Vaccine 27: 5906-5912.

44.

Dobano, C., Widera, G., Rabussay, D., and Doolan, D. L. (2007).
Enhancement of antibody and cellular immune responses to
malaria DNA vaccines by in vivo electroporation. Vaccine 25:
6635-6645.

93

45.

Luxembourg, A., Hannaman D, Nolan E, Ellefsen B, Nakamura G,
Chau L, Tellez O, Little S, Bernard R. (2008). Potentiation of an
anthrax DNA vaccine with electroporation. Vaccine 26: 52165222.

46.

Trollet, C., Pereira Y, Burgain A, Litzler E, Mezrahi M, Seguin J,
Manich M, Popoff MR, Scherman D, Bigey P. (2009). Generation
of high-titer neutralizing antibodies against botulinum toxins A,
B, and E by DNA electrotransfer. Infect Immun 77: 2221-2229.

47.

Tollefsen, S., Tjelle T, Schneider J, Harboe M, Wiker H, Hewinson
G, Huygen K, Mathiesen I. (2002). Improved cellular and
humoral immune responses against Mycobacterium tuberculosis
antigens after intramuscular DNA immunization combined with
muscle electroporation. Vaccine 20: 3370-3378.

48.

Drabick, J. J., Glasspool-Malone, J., King, A., and Malone, R. W.
(2001). Cutaneous transfection and immune responses to
intradermal nucleic acid vaccination are significantly enhanced
by in vivo electropermeabilization. MolTher 3: 249-255.

49.

Dujardin, N., Van Der Smissen, P., and Preat, V. (2001). Topical
gene transfer into rat skin using electroporation. Pharm Res 18:
61-66.

50.

Heller, R., Schultz J, Lucas ML, Jaroszeski MJ, Heller LC, Gilbert
RA, Moelling K, Nicolau C. (2001). Intradermal delivery of
interleukin-12 plasmid DNA by in vivo electroporation.DNA Cell
Biol 20: 21-26.

51.

Zhang, L., Nolan, E., Kreitschitz, S., and Rabussay, D. P. (2002).
Enhanced delivery of naked DNA to the skin by non-invasive in
vivo electroporation. BiochimBiophysActa 1572: 1-9.

52.

Maruyama, H., Ataka, K., Higuchi, N., Sakamoto, F., Gejyo, F.,
and Miyazaki, J. (2001). Skin-targeted gene transfer using in
vivo electroporation. Gene Ther 8: 1808-1812.

53.

Glasspool-Malone, J., Somiari, S., Drabick, J. J., and Malone, R.
W. (2000). Efficient nonviral cutaneous transfection. MolTher 2:
140-146.

94

54.

Daud, A. I., DeConti RC, Andrews S, Urbas P, Riker AI, Sondak
VK, Munster PN, Sullivan DM, Ugen KE, Messina JL, Heller R.
(2008). Phase I trial of interleukin-12 plasmid electroporation in
patients with metastatic melanoma. J ClinOncol 26: 5896-5903.

55.

Heller, R., Cruz, Y., Heller, L. C., Gilbert, R. A., and Jaroszeski,
M. J. ( 2010) Electrically mediated delivery of plasmid DNA to
the skin, using a multielectrode array. Hum Gene Ther 21: 357362.

56.

Medi, B. M., and Singh, J. (2008). Delivery of DNA into skin via
electroporation. Methods MolBiol 423: 225-232.
Peachman, K. K., Rao, M., and Alving, C. R. (2003).
Immunization with DNA through the skin. Methods 31: 232-242.

57.
58.

Gilbert, R. A., Jaroszeski, M. J., and Heller, R. (1997). Novel
electrode designs for electrochemotherapy. BiochimBiophysActa
1334: 9-14.

59.

Iizuka, H. (1994). Epidermal turnover time. J DermatolSci
8:215-217.

60.

Gothelf, A., and Gehl, J. (2011) Gene electrotransfer to skin;
review of existing literature and clinical perspectives. Curr Gene
Ther 10: 287-299.

61.

Monteiro-Riviere, N. A., Van Miller, J. P., Simon, G., Joiner, R. L.,
Brooks, J. D., and Riviere, J. E. (2000). Comparative in vitro
percutaneous absorption of nonylphenol and
nonylphenolethoxylates (NPE-4 and NPE-9) through human,
porcine and rat skin. ToxicolInd Health 16: 49-57.

62.

Riviere, J. E. (1996). Isolated perfused porcine skin flap
systems. Pharm Biotechnol 8: 387-407.

63.

Sueki, H., Gammal, C., Kudoh, K., and Kligman, A. M. (2000).
Hairless guinea pig skin: anatomical basis for studies of
cutaneous biology. Eur J Dermatol 10: 357-364.

64.

Gothelf, A., Mahmood, F., Dagnaes-Hansen, F., and Gehl, J.
(2011) Efficacy of transgene expression in porcine skin as a
function of electrode choice. Bioelectrochemistry.

95

65.

Ferraro, B., Heller, L. C., Cruz, Y. L., Guo, S., Donate, A., and
Heller, R. (2010) Evaluation of delivery conditions for cutaneous
plasmid electrotransfer using a multielectrode array. Gene Ther
18: 496-500.

66.

Beatty, M. E., Ashford, D. A., Griffin, P. M., Tauxe, R. V., and
Sobel, J. (2003). Gastrointestinal anthrax: review of the
literature. Arch Intern Med 163: 2527-2531.

67.

Driks, A. (2009). The Bacillus anthracis spore. Mol Aspects Med
30: 368-373.

68.

Bozue, J., Moody KL, Cote CK, Stiles BG, Friedlander AM, Welkos
SL, Hale ML. (2007). Bacillus anthracis spores of the bclA mutant
exhibit increased adherence to epithelial cells, fibroblasts, and
endothelial cells but not to macrophages. Infect Immun 75:
4498-4505.

69.

Petosa, C., Collier, R. J., Klimpel, K. R., Leppla, S. H., and
Liddington, R. C. (1997). Crystal structure of the anthrax toxin
protective antigen. Nature 385: 833-838.

70.

Kintzer, A. F., Sterling HJ, Tang II, Abdul-Gader A, Miles AJ,
Wallace BA, Williams ER, Krantz BA. (2010). Role of the
protective antigen octamer in the molecular mechanism of
anthrax lethal toxin stabilization in plasma. J MolBiol 399: 741758.

71.

Kintzer, A. F., Sterling, H. J., Tang, II, Williams, E. R., and
Krantz, B. A. (2010). Anthrax toxin receptor drives protective
antigen oligomerization and stabilizes the heptameric and
octameric oligomer by a similar mechanism. PLoS One 5:
e13888.

72.

Kintzer, A. F., Thoren KL, Sterling HJ, Dong KC, Feld GK, Tang
II, Zhang TT, Williams ER, Berger JM, Krantz BA. (2009). The
protective antigen component of anthrax toxin forms functional
octameric complexes. J MolBiol 392: 614-629.

73.

Krantz, B. A., Finkelstein, A., and Collier, R. J. (2006). Protein
translocation through the anthrax toxin transmembrane pore is
driven by a proton gradient. J MolBiol 355: 968-979.

96

74.

Krantz, B. A., et al. (2005). A phenylalanine clamp catalyzes
protein translocation through the anthrax toxin pore. Science
309: 777-781.

75.

Thoren, K. L., Worden, E. J., Yassif, J. M., and Krantz, B. A.
(2009). Lethal factor unfolding is the most force-dependent step
of anthrax toxin translocation. ProcNatlAcadSci U S A 106:
21555-21560.

76.

Pezard, C., Berche, P., and Mock, M. (1991). Contribution of
individual toxin components to virulence of Bacillus anthracis.
Infect Immun 59: 3472-3477.

77.

Duesbery, N. S., and VandeWoude, G. F. (1999). Anthrax lethal
factor causes proteolytic inactivation of mitogen-activated
protein kinase kinase. J ApplMicrobiol 87: 289-293.
Kalamas, A. G. (2004). Anthrax. AnesthesiolClin North America
22: 533-540, vii.

78.
79.

Doganay, M., Metan, G., and Alp, E. A review of cutaneous
anthrax and its outcome. (2010). J Infect Public Health 3: 98105.

80.

Puziss, M., and Wright, G. G. (1954). Studies on immunity in
anthrax. IV. Factors influencing elaboration of the protective
antigen of bacillus anthracis in chemically defined media. J
Bacteriol 68: 474-482.

81.

Wright, G. G., Green, T. W., and Kanode, R. G., Jr. (1954).
Studies on immunity in anthrax. V. Immunizing activity of alumprecipitated protective antigen. J Immunol 73: 387-391.

82.

Wright, G. G., Hedberg, M. A., and Feinberg, R. J. (1951).
Studies on immunity in anthrax. II. In vitro elaboration of
protective antigen by non-proteolytic mutants of Bacillus
anthracis. J Exp Med
93: 523-527.

83.

Wright, G. G., Hedberg, M. A., and Slein, J. B. (1954).Studies on
immunity in anthrax. III. Elaboration of protective antigen in a
chemically defined, non-protein medium. J Immunol 72: 263269.

97

84.

Wright, G. G., and Slein, J. B. (1951). Studies on immunity in
anthrax. I. Variation in the serum T-agglutinin during anthrax
infection in the rabbit. J Exp Med 93: 99-106.

85.

Auerbach, S., and Wright, G. G. (1955). Studies on immunity in
anthrax. VI. Immunizing activity of protective antigen against
various strains of Bacillus anthracis. J Immunol 75: 129-133.

86.

Wasserman, G. M., Grabenstein JD, Pittman PR, Rubertone MV,
Gibbs PP, Wang LZ, Golder LG. (2003). Analysis of adverse
events after anthrax immunization in US Army medical
personnel. J Occup Environ Med 45: 222-233.

87.

Ivins, B. E., Ezzell, J. W., Jr., Jemski, J., Hedlund, K. W.,
Ristroph, J. D., and Leppla, S. H. (1986). Immunization studies
with attenuated strains of Bacillus anthracis. Infect Immun 52:
454-458.

88.

Duesbery, N. S., and VandeWoude, G. F. (1999). Anthrax toxins.
Cell Mol Life Sci 55: 1599-1609.
Friedlander, A. M., and Little, S. F. (2009). Advances in the
development of next-generation anthrax vaccines. Vaccine 27
Suppl 4: D28-32.

89.

90.

Brown, B. K., Cox J, Gillis A, VanCott TC, Marovich M, Milazzo M,
Antonille TS, Wieczorek L, McKee KT Jr, Metcalfe K, Mallory RM,
Birx D, Polonis VR, Robb ML. (2010). Phase I study of safety and
immunogenicity of an Escherichia coli-derived recombinant
protective antigen (rPA) vaccine to prevent anthrax in adults.
PLoS One 5: e13849.

91.

Baillie, L. W., Huwar TB, Moore S, Mellado-Sanchez G, Rodriguez
L, Neeson BN, Flick-Smith HC, Jenner DC, Atkins HS, Ingram RJ,
Altmann DM, Nataro JP, Pasetti MF. (2010). An anthrax subunit
vaccine candidate based on protective regions of Bacillus
anthracis protective antigen and lethal factor. Vaccine 28: 67406748.

92.

Oscherwitz, J., Yu, F., and Cease, K. B. (2010). A synthetic
peptide vaccine directed against the 2ss2-2ss3 loop of domain 2
of protective antigen protects rabbits from inhalation anthrax. J
Immunol 185: 3661-3668.

98

93.

Livingston, B. D., Little, S. F., Luxembourg, A., Ellefsen, B., and
Hannaman, D. (2010). Comparative performance of a licensed
anthrax vaccine versus electroporation based delivery of a PA
encoding DNA vaccine in rhesus macaques. Vaccine 28: 10561061.

94.

Dienstag, J. L. (1978). Hepatitis B virus infection: more than
meets the eye. Gastroenterology 75: 1172-1174.

95.

Grimm, D., Thimme, R., and Blum, H. E. (2011). HBV life cycle
and novel drug targets. HepatolInt 5: 644-653.

96.

Elamin, S., and Abu-Aisha, H. (2011). Prevention of hepatitis B
virus and hepatitis C virus transmission in hemodialysis centers:
review of current international recommendations. Arab J Nephrol
Transplant 4: 35-47.

97.

Donate, A., Coppola, D., Cruz, Y., and Heller, R. Evaluation of a
novel non-penetrating electrode for use in DNA vaccination.
(2011). PLoS One 6: e19181.

98.

Tuting, T., et al. (1998). DNA vaccines targeting dendritic cells
for the immunotherapy of cancer. AdvExp Med Biol 451: 295304.
Hahn, U. K., Alex, M., Czerny, C. P., Bohm, R., and Beyer, W.
(2004). Protection of mice against challenge with Bacillus
anthracis STI spores after DNA vaccination. Int J Med Microbiol
294: 35-44.

99.

100. Hahn, U. K., Boehm, R., and Beyer, W. (2006). DNA vaccination
against anthrax in mice-combination of anti-spore and anti-toxin
components. Vaccine 24: 4569-4571.
101. Roos, A. K., Eriksson F, Timmons JA, Gerhardt J, Nyman U,
Gudmundsdotter L, Bråve A, Wahren B, Pisa P. (2009). Skin
electroporation: effects on transgene expression, DNA
persistence and local tissue environment. PLoS One 4: e7226.
102. Williamson, E. D., Bennett, A. M., Perkins, S. D., Beedham, R. J.,
Miller, J., and Baillie, L. W. (2002). Co-immunisation with a
plasmid DNA cocktail primes mice against anthrax and plague.
Vaccine 20: 2933-2941.

99

103. Zhang, J., et al. (2006). The 2beta2-2beta3 loop of anthrax
protective antigen contains a dominant neutralizing epitope.
BiochemBiophys Res Commun 341: 1164-1171.
104. Ribeiro, S., Rijpkema, S. G., Durrani, Z., and Florence, A. T.
(2007). PLGA-dendron nanoparticles enhance immunogenicity
but not lethal antibody production of a DNA vaccine against
anthrax in mice. Int J Pharm 331: 228-232.
105. Shaker, D. S., et al. (2007). Immunization by application of DNA
vaccine onto a skin area wherein the hair follicles have been
induced into anagen-onset stage. MolTher 15: 2037-2043.
106. Yu, Y. Z., Li N, Wang WB, Wang S, Ma Y, Yu WY, Sun ZW.
(2010). Distinct immune responses of recombinant plasmid DNA
replicon vaccines expressing two types of antigens with or
without signal sequences. Vaccine 28: 7529-7535.
107. Midha, S., and Bhatnagar, R. (2009). Genetic immunization with
GPI-anchored anthrax protective antigen raises combined CD1dand MHC II-restricted antibody responses by natural killer T cellmediated help. Vaccine 27: 1700-1709.
108. Midha, S., and Bhatnagar, R. (2009). Anthrax protective antigen
administered by DNA vaccination to distinct subcellular locations
potentiates humoral and cellular immune responses. Eur J
Immunol 39: 159-177.
109. McConnell, M. J., Hanna, P. C., and Imperiale, M. J. (2007).
Adenovirus-based prime-boost immunization for rapid
vaccination against anthrax. MolTher 15: 203-210.
110. Park, Y. S., Lee, J. H., Hung, C. F., Wu, T. C., and Kim, T. W.
(2008). Enhancement of antibody responses to Bacillus anthracis
protective antigen domain IV by use of calreticulin as a chimeric
molecular adjuvant.Infect Immun 76: 1952-1959.
111. Welkos, S. L., Keener, T. J., and Gibbs, P. H. (1986). Differences
in susceptibility of inbred mice to Bacillus anthracis. Infect
Immun 51: 795-800.
112. Fattori, E., La Monica, N., Ciliberto, G., and Toniatti, C. (2002).
Electro-gene-transfer: a new approach for muscle gene delivery.
Somat Cell Mol Genet 27: 75-83.
100

113. Martinon, F., Kaldma K, Sikut R, Culina S, Romain G, Tuomela M,
Adojaan M, Männik A, Toots U, Kivisild T, Morin J, Brochard P,
Delache B, Tripiciano A, Ensoli F, Stanescu I, Le Grand R, Ustav
M. (2009). Persistent immune responses induced by a human
immunodeficiency virus DNA vaccine delivered in association
with electroporation in the skin of nonhuman primates. Hum
Gene Ther 20: 1291-1307.
114. Medi, B. M., Hoselton, S., Marepalli, R. B., and Singh, J. (2005).
Skin targeted DNA vaccine delivery using electroporation in
rabbits. I: efficacy. Int J Pharm 294: 53-63.
115. Vandermeulen, G., Staes, E., Vanderhaeghen, M. L., Bureau, M.
F., Scherman, D., and Preat, V. (2007). Optimisation of
intradermal DNA electrotransfer for immunisation. J Control
Release 124: 81-87.
116. Hirao, L. A., Wu, L., Khan, A. S., Satishchandran, A., DraghiaAkli, R., and Weiner, D. B. (2008). Intradermal/subcutaneous
immunization by electroporation improves plasmid vaccine
delivery and potency in pigs and rhesus macaques. Vaccine 26:
440-448.
117. Makidon, P. E., Bielinska AU, Nigavekar SS, Janczak KW,
Knowlton J, Scott AJ, Mank N, Cao Z, Rathinavelu S, Beer MR,
Wilkinson JE, Blanco LP, Landers JJ, Baker JR Jr. (2008). Preclinical evaluation of a novel nanoemulsion-based hepatitis B
mucosal vaccine. PLoS One 3: e2954.
118. Muttil, P., Prego C, Garcia-Contreras L, Pulliam B, Fallon JK,
Wang C, Hickey AJ, Edwards D. (2010). Immunization of guinea
pigs with novel hepatitis B antigen as nanoparticle aggregate
powders administered by the pulmonary route. AAPS J 12: 330337.
119. Babiuk, S., Baca-Estrada, M. E., Pontarollo, R., and Foldvari, M.
(2002). Topical delivery of plasmid DNA using biphasic lipid
vesicles (Biphasix).J Pharm Pharmacol 54: 1609-1614.

101

120. Broderick, K. E., Shen X, Soderholm J, Lin F, McCoy J, Khan AS,
Yan J, Morrow MP, Patel A, Kobinger GP, Kemmerrer S, Weiner
DB, Sardesai NY. (2011). Prototype development and preclinical
immunogenicity analysis of a novel minimally invasive
electroporation device. Gene Ther 18: 258-265.
121. Lu, S., Santoro, J. C., Fuller, D. H., Haynes, J. R., and Robinson,
H. L. (1995). Use of DNAs expressing HIV-1 Env and
noninfectious HIV-1 particles to raise antibody responses in
mice. Virology 209: 147-154.
122. Wang, B., Ugen KE, Srikantan V, Agadjanyan MG, Dang K,
Refaeli Y, Sato AI, Boyer J, Williams WV, Weiner DB. (1993).
Gene inoculation generates immune responses against human
immunodeficiency virus type 1. Proc Natl Acad Sci U S A 90:
4156-4160.
123. Luke, C. J., Carner, K., Liang, X., and Barbour, A. G. (1997). An
OspA-based DNA vaccine protects mice against infection with
Borrelia burgdorferi. J Infect Dis 175: 91-97.
124. Zhong, W., Wiesmuller, K. H., Kramer, M. D., Wallich, R., and
Simon, M. M. (1996). Plasmid DNA and protein vaccination of
mice to the outer surface protein A of Borrelia burgdorferi leads
to induction of T helper cells with specificity for a major epitope
and augmentation of protective IgG antibodies in vivo. Eur J
Immunol 26: 2749-2757.
125. Hedstrom, R. C., Doolan DL, Wang R, Kumar A, Sacci JB Jr,
Gardner MJ, Aguiar JC, Charoenvit Y, Sedegah M, Tine JA,
Margalith M, Hobart P, Hoffman SL. (1998). In vitro expression
and in vivo immunogenicity of Plasmodium falciparum preerythrocytic stage DNA vaccines. Int J Mol Med 2: 29-38.
126. Yang, Z. Y., Kong WP, Huang Y, Roberts A, Murphy BR,
Subbarao K, Nabel GJ. (2004). A DNA vaccine induces SARS
coronavirus neutralization and protective immunity in mice.
Nature 428: 561-564.
127. Zeng, F., Chow KY, Hon CC, Law KM, Yip CW, Chan KH, Peiris JS,
Leung FC. (2004). Characterization of humoral responses in mice
immunized with plasmid DNAs encoding SARS-CoV spike gene
fragments. Biochem Biophys Res Commun 315: 1134-1139.

102

128. Zhao, B., Jin, N. Y., Wang, R. L., Zhang, L. S., and Zhang, Y. J.
(2006). Immunization of mice with a DNA vaccine based on
severe acute respiratory syndrome coronavirus spike protein
fragment 1. Viral Immunol 19: 518-524.
129. Anderson, R., Gao, X. M., Papakonstantinopoulou, A.,
Fairweather, N., Roberts, M., and Dougan, G. (1997).
Immunization of mice with DNA encoding fragment C of tetanus
toxin. Vaccine 15: 827-829.
130. Campos-Neto, A., Webb, J. R., Greeson, K., Coler, R. N., Skeiky,
Y. A., and Reed, S. G. (2002). Vaccination with plasmid DNA
encoding TSA/LmSTI1 leishmania fusion proteins confers
protection against Leishmania major infection in susceptible
BALB/c mice. Infect Immun 70: 2828-2836.
131. Lopez-Fuertes, L., Pérez-Jiménez E, Vila-Coro AJ, Sack F, Moreno
S, Konig SA, Junghans C, Wittig B, Timón M, Esteban M. (2002).
DNA vaccination with linear minimalistic (MIDGE) vectors confers
protection against Leishmania major infection in mice. Vaccine
21: 247-257.
132. Sukumaran, B., Tewary, P., Saxena, S., and Madhubala, R.
(2003). Vaccination with DNA encoding ORFF antigen confers
protective immunity in mice infected with Leishmania donovani.
Vaccine 21: 1292-1299.
133. Yankauckas, M. A., Morrow JE, Parker SE, Abai A, Rhodes GH,
Dwarki VJ, Gromkowski SH. (1993). Long-term antinucleoprotein cellular and humoral immunity is induced by
intramuscular injection of plasmid DNA containing NP gene. DNA
Cell Biol 12: 771-776.
134. Ulmer, J. B., Donnelly JJ, Parker SE, Rhodes GH, Felgner PL,
Dwarki VJ, Gromkowski SH, Deck RR, DeWitt CM, Friedman A, et
al. (1993). Heterologous protection against influenza by injection
of DNA encoding a viral protein. Science 259: 1745-1749.
135. Robinson, H. L., Hunt, L. A., and Webster, R. G. (1993).
Protection against a lethal influenza virus challenge by
immunization with a haemagglutinin-expressing plasmid DNA.
Vaccine 11: 957-960.

103

136. Huygen, K., Content J, Denis O, Montgomery DL, Yawman AM,
Deck RR, DeWitt CM, Orme IM, Baldwin S, D'Souza C, Drowart
A, Lozes E, Vandenbussche P, Van Vooren JP, Liu MA, Ulmer JB.
(1996). Immunogenicity and protective efficacy of a tuberculosis
DNA vaccine. Nat Med 2: 893-898.
137. Lozes, E., Huygen K, Content J, Denis O, Montgomery DL,
Yawman AM, Vandenbussche P, Van Vooren JP, Drowart A,
Ulmer JB, Liu MA. (1997). Immunogenicity and efficacy of a
tuberculosis DNA vaccine encoding the components of the
secreted antigen 85 complex. Vaccine 15: 830-833.
138. Montgomery, D. L., Huygen K, Yawman AM, Deck RR, Dewitt CM,
Content J, Liu MA, Ulmer JB. (1997). Induction of humoral and
cellular immune responses by vaccination with M. tuberculosis
antigen 85 DNA. Cell Mol Biol (Noisy-le-grand) 43: 285-292.
139. Tascon, R. E., Colston, M. J., Ragno, S., Stavropoulos, E.,
Gregory, D., and Lowrie, D. B. (1996). Vaccination against
tuberculosis by DNA injection. Nat Med 2: 888-892.
140. Ulmer, J. B., Liu MA, Montgomery DL, Yawman AM, Deck RR,
DeWitt CM, Content J, Huygen K. (1997). Expression and
immunogenicity of Mycobacterium tuberculosis antigen 85 by
DNA vaccination. Vaccine 15: 792-794.
141. Angus, C. W., Klivington, D., Wyman, J., and Kovacs, J. A.
(1996). Nucleic acid vaccination against Toxoplasma gondii in
mice. J Eukaryot Microbiol 43: 117S.
142. Angus, C. W., Klivington-Evans, D., Dubey, J. P., and Kovacs, J.
A. (2000). Immunization with a DNA plasmid encoding the SAG1
(P30) protein of Toxoplasma gondii is immunogenic and
protective in rodents. J Infect Dis 181: 317-324.
143. Desolme, B., Mevelec, M. N., Buzoni-Gatel, D., and Bout, D.
(2000). Induction of protective immunity against toxoplasmosis
in mice by DNA immunization with a plasmid encoding
Toxoplasma gondii GRA4 gene. Vaccine 18: 2512-2521.

104

144. Guo, H., Chen, G., Lu, F., Chen, H., and Zheng, H. (2001).
Immunity induced by DNA vaccine of plasmid encoding the
rhoptry protein 1 gene combined with the genetic adjuvant of
pcIFN-gamma against Toxoplasma gondii in mice. Chin Med J
(Engl) 114: 317-320.
145. Leyva, R., Herion, P., and Saavedra, R. (2001). Genetic
immunization with plasmid DNA coding for the ROP2 protein of
Toxoplasma gondii. Parasitol Res 87: 70-79.
146. Vercammen, M., Scorza T, Huygen K, De Braekeleer J, Diet R,
Jacobs D, Saman E, Verschueren H. (2000). DNA vaccination
with genes encoding Toxoplasma gondii antigens GRA1, GRA7,
and ROP2 induces partially protective immunity against lethal
challenge in mice. Infect Immun 68: 38-45.
147. Ray, N. B., Ewalt, L. C., and Lodmell, D. L. (1997). Nanogram
quantities of plasmid DNA encoding the rabies virus glycoprotein
protect mice against lethal rabies virus infection. Vaccine 15:
892-895.
148. Osorio, J. E., Tomlinson CC, Frank RS, Haanes EJ, Rushlow K,
Haynes JR, Stinchcomb DT. (1999). Immunization of dogs and
cats with a DNA vaccine against rabies virus. Vaccine 17: 11091116.
149. Price, B. M., Liner, A. L., Park, S., Leppla, S. H., Mateczun, A.,
and Galloway, D. R. (2001). Protection against anthrax lethal
toxin challenge by genetic immunization with a plasmid encoding
the lethal factor protein. Infect Immun 69: 4509-4515.
150. Gu, M. L., Leppla, S. H., and Klinman, D. M. (1999). Protection
against anthrax toxin by vaccination with a DNA plasmid
encoding anthrax protective antigen. Vaccine 17: 340-344.
151. Drew, D. R., Lightowlers, M., and Strugnell, R. A. (2000).
Humoral immune responses to DNA vaccines expressing
secreted, membrane bound and non-secreted forms of the Tania
ovis 45W antigen. Vaccine 18: 2522-2532.

105

152. Whalen, R. G., Leclerc, C., Deriaud, E., Schirmbeck, R.,
Reimann, J., and Davis, H. L. (1995). DNA-mediated
immunization to the hepatitis B surface antigen. Activation and
entrainment of the immune response. Ann N Y Acad Sci 772: 6476.
153. Davis, H. L., Demeneix, B. A., Quantin, B., Coulombe, J., and
Whalen, R. G. (1993). Plasmid DNA is superior to viral vectors
for direct gene transfer into adult mouse skeletal muscle. Hum
Gene Ther 4: 733-740.
154. Davis, H. L., Michel, M. L., Mancini, M., Schleef, M., and Whalen,
R. G. (1994). Direct gene transfer in skeletal muscle: plasmid
DNA-based immunization against the hepatitis B virus surface
antigen. Vaccine 12: 1503-1509.
155.

Bennett, A. M., Perkins, S. D., and Holley, J. L. (2003). DNA
vaccination protects against botulinum neurotoxin type F.
Vaccine 21: 3110-3117.

156. Yu, Y. Z., Zhang, S. M., Sun, Z. W., Wang, S., and Yu, W. Y.
(2007). Enhanced immune responses using plasmid DNA
replicon vaccine encoding the Hc domain of Clostridium
botulinum neurotoxin serotype A. Vaccine 25: 8843-8850.
157. Dupre, L., Poulain-Godefroy O, Ban E, Ivanoff N, Mekranfar M,
Schacht AM, Capron A, Riveau G. (1997). Intradermal
immunization of rats with plasmid DNA encoding Schistosoma
mansoni 28 kDa glutathione S-transferase. Parasite Immunol
19: 505-513.
158. Nascimento, E., Leão IC, Pereira VR, Gomes YM, Chikhlikar P,
August T, Marques E, Lucena-Silva N. (2002). Protective
immunity of single and multi-antigen DNA vaccines against
schistosomiasis. Mem Inst Oswaldo Cruz 97 Suppl 1: 105-109.
159. Inchauspe, G., Major, M. E., Nakano, I., Vitvitski, L., and Trepo,
C. (1997). DNA vaccination for the induction of immune
responses against hepatitis C virus proteins. Vaccine 15: 853856.

106

160. Nakano, I., Maertens G, Major ME, Vitvitski L, Dubuisson J,
Fournillier A, De Martynoff G, Trepo C, Inchauspe G. (1997).
Immunization with plasmid DNA encoding hepatitis C virus
envelope E2 antigenic domains induces antibodies whose
immune reactivity is linked to the injection mode. J Virol 71:
7101-7109.
161. Riemenschneider, J., Garrison A, Geisbert J, Jahrling P, Hevey M,
Negley D, Schmaljohn A, Lee J, Hart MK, Vanderzanden L,
Custer D, Bray M, Ruff A, Ivins B, Bassett A, Rossi C,
Schmaljohn C. (2003). Comparison of individual and combination
DNA vaccines for B. anthracis, Ebola virus, Marburg virus and
Venezuelan equine encephalitis virus. Vaccine 21: 4071-4080.
162. Manickan, E., Yu, Z., Rouse, R. J., Wire, W. S., and Rouse, B. T.
(1995). Induction of protective immunity against herpes simplex
virus with DNA encoding the immediate early protein ICP 27.
Viral Immunol 8: 53-61.
163. Bourne, N., Stanberry, L. R., Bernstein, D. I., and Lew, D.
(1996). DNA immunization against experimental genital herpes
simplex virus infection. J Infect Dis 173: 800-807.
164. Wlazlo, A. P., Deng, H., Giles-Davis, W., and Ertl, H. C. (2004).
DNA vaccines against the human papillomavirus type 16 E6 or
E7 oncoproteins. Cancer Gene Ther 11: 457-464.
165. Cao, F., Li XF, Yu XD, Deng YQ, Jiang T, Zhu QY, Qin ED, Qin CF.
(2011). A DNA-based West Nile virus replicon elicits humoral
and cellular immune responses in mice. J Virol Methods 178: 8793.
166. Herrmann, J. E., Chen, S. C., Fynan, E. F., Santoro, J. C.,
Greenberg, H. B., and Robinson, H. L. (1996). DNA vaccines
against rotavirus infections. Arch Virol Suppl 12: 207-215.
167. Herrmann, J. E., et al. (1996). Protection against rotavirus
infections by DNA vaccination. J Infect Dis 174 Suppl 1: S93-97.
168. Phillpotts, R. J., Venugopal, K., and Brooks, T. (1996).
Immunisation with DNA polynucleotides protects mice against
lethal challenge with St. Louis encephalitis virus. Arch Virol 141:
743-749.
107

Appendices

108

Appendix A: Publications and Posters by Author
Primary Articles

Donate, A., Heller, R. Non-invasive electrically mediate DNA Vaccine
against B. anthracis. Submitted Oct. 2011, Molecular Therapy.

Donate A., Coppola D., Cruz Y., Heller R. Evaluation of a novel nonpenetrating electrode for use in DNA vaccination. PLoS One. 2011 Apr
29;6(4):e19181

Guo S., Donate A., Basu G., Lundberg C., Heller L., Heller R.(2011).
Electro-gene transfer to skin using a non-invasive multi-electrode
array. J Control Release.2011 May 10;151(3):256-62. Epub 2011 Jan
22

Ferraro B., Heller L., Cruz Y., Guo S., Donate A., Heller R. (2010)
Evaluation of delivery conditions for cutaneous plasmid electrotransfer
using a multi-electrode array. Gene Therapy 2011 May;18(5):496500. Epub 2010 Dec 23
109

Poster Presentations

Donate, A.; Heller, R. Electrically Induced DNA Vaccine Against
Bacillus anthracis. American Society for Microbiology General Meeting
May 2011.

Donate, A.; Heller, R. The Multi-Electrode Array: Evaluation of a NonPenetrating Electrode for Use in DNA Vaccination Against Bacillus
anthracis. Gordon Research Conference on Bioelectrochemistry 2010

Donate, A.; Heller, R. Optimization of the multi-electrode array in a
mouse model for use in DNA vaccination against Bacillus anthracis.
International Consortium for Bioelectrics Annual Symposium 2010

Donate, A.; Heller, R. Non-invasive electrically induced DNA vaccine
against Bacillus anthracis. American Society for Microbiology:
Biodefense 2010

Donate, A.; Heller, R. Evaluation of the multi-electrode array for use
in DNA vaccination against Bacillus anthracis. American Society for
Gene Therapy 13th Annual Meeting 2010

110

Donate, A.; Cruz, Y.; Coppola, D.; Heller, R. Evaluation of the
conformable array for use in DNA vaccination. Gordon Research
Conference on Bioelectrochemistry 2008

Donate, A.; Cruz, Y.; Heller, R. Evaluation of cutaneous
administration of DNA vaccines delivered by electroporation. Florida
Center of excellence 1st annual symposium 2007

Oral Presentations

Donate, A.; Heller, R. The Multi-Electrode Array: Evaluation of a
Non-Penetrating Electrode for Use in DNA Vaccination Against Bacillus
anthracis. Gordon- Kennan Research Symposium 2010

Donate, A; Cruz, Y.; Coppola, D.; Heller, R. Evaluation of Cutaneous
Administration of DNA vaccines delivered by electroporation.
American Society for Gene Therapy 11th Annual Meeting 2008

111

Appendix B: License Permissions for Reprint
Creative Commons License
Attribution 3.0 Unported
CREATIVE COMMONS CORPORATION IS NOT A LAW FIRM AND DOES
NOT PROVIDE LEGAL SERVICES. DISTRIBUTION OF THIS LICENSE
DOES NOT CREATE AN ATTORNEY-CLIENT RELATIONSHIP. CREATIVE
COMMONS PROVIDES THIS INFORMATION ON AN "AS-IS" BASIS.
CREATIVE COMMONS MAKES NO WARRANTIES REGARDING THE
INFORMATION PROVIDED, AND DISCLAIMS LIABILITY FOR DAMAGES
RESULTING FROM ITS USE.
License
THE WORK (AS DEFINED BELOW) IS PROVIDED UNDER THE TERMS
OF THIS CREATIVE COMMONS PUBLIC LICENSE ("CCPL" OR
"LICENSE"). THE WORK IS PROTECTED BY COPYRIGHT AND/OR
OTHER APPLICABLE LAW. ANY USE OF THE WORK OTHER THAN AS
AUTHORIZED UNDER THIS LICENSE OR COPYRIGHT LAW IS
PROHIBITED.
BY EXERCISING ANY RIGHTS TO THE WORK PROVIDED HERE, YOU
ACCEPT AND AGREE TO BE BOUND BY THE TERMS OF THIS LICENSE.
TO THE EXTENT THIS LICENSE MAY BE CONSIDERED TO BE A
CONTRACT, THE LICENSOR GRANTS YOU THE RIGHTS CONTAINED
HERE IN CONSIDERATION OF YOUR ACCEPTANCE OF SUCH TERMS
AND CONDITIONS.
1. Definitions
a. "Adaptation" means a work based upon the Work, or upon the
Work and other pre-existing works, such as a translation,
adaptation, derivative work, arrangement of music or other
alterations of a literary or artistic work, or phonogram or
performance and includes cinematographic adaptations or any
other form in which the Work may be recast, transformed, or
adapted including in any form recognizably derived from the
original, except that a work that constitutes a Collection will not
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b.

c.
d.
e.

f.

be considered an Adaptation for the purpose of this License. For
the avoidance of doubt, where the Work is a musical work,
performance or phonogram, the synchronization of the Work in
timed-relation with a moving image ("synching") will be
considered an Adaptation for the purpose of this License.
"Collection" means a collection of literary or artistic works,
such as encyclopedias and anthologies, or performances,
phonograms or broadcasts, or other works or subject matter
other than works listed in Section 1(f) below, which, by reason
of the selection and arrangement of their contents, constitute
intellectual creations, in which the Work is included in its entirety
in unmodified form along with one or more other contributions,
each constituting separate and independent works in
themselves, which together are assembled into a collective
whole. A work that constitutes a Collection will not be considered
an Adaptation (as defined above) for the purposes of this
License.
"Distribute" means to make available to the public the original
and copies of the Work or Adaptation, as appropriate, through
sale or other transfer of ownership.
"Licensor" means the individual, individuals, entity or entities
that offer(s) the Work under the terms of this License.
"Original Author" means, in the case of a literary or artistic
work, the individual, individuals, entity or entities who created
the Work or if no individual or entity can be identified, the
publisher; and in addition (i) in the case of a performance the
actors, singers, musicians, dancers, and other persons who act,
sing, deliver, declaim, play in, interpret or otherwise perform
literary or artistic works or expressions of folklore; (ii) in the
case of a phonogram the producer being the person or legal
entity who first fixes the sounds of a performance or other
sounds; and, (iii) in the case of broadcasts, the organization that
transmits the broadcast.
"Work" means the literary and/or artistic work offered under
the terms of this License including without limitation any
production in the literary, scientific and artistic domain, whatever
may be the mode or form of its expression including digital form,
such as a book, pamphlet and other writing; a lecture, address,
sermon or other work of the same nature; a dramatic or
dramatico-musical work; a choreographic work or entertainment
in dumb show; a musical composition with or without words; a
cinematographic work to which are assimilated works expressed
by a process analogous to cinematography; a work of drawing,
painting, architecture, sculpture, engraving or lithography; a
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photographic work to which are assimilated works expressed by
a process analogous to photography; a work of applied art; an
illustration, map, plan, sketch or three-dimensional work relative
to geography, topography, architecture or science; a
performance; a broadcast; a phonogram; a compilation of data
to the extent it is protected as a copyrightable work; or a work
performed by a variety or circus performer to the extent it is not
otherwise considered a literary or artistic work.
g. "You" means an individual or entity exercising rights under this
License who has not previously violated the terms of this License
with respect to the Work, or who has received express
permission from the Licensor to exercise rights under this
License despite a previous violation.
h. "Publicly Perform" means to perform public recitations of the
Work and to communicate to the public those public recitations,
by any means or process, including by wire or wireless means or
public digital performances; to make available to the public
Works in such a way that members of the public may access
these Works from a place and at a place individually chosen by
them; to perform the Work to the public by any means or
process and the communication to the public of the
performances of the Work, including by public digital
performance; to broadcast and rebroadcast the Work by any
means including signs, sounds or images.
i. "Reproduce" means to make copies of the Work by any means
including without limitation by sound or visual recordings and the
right of fixation and reproducing fixations of the Work, including
storage of a protected performance or phonogram in digital form
or other electronic medium.
2. Fair Dealing Rights. Nothing in this License is intended to reduce,
limit, or restrict any uses free from copyright or rights arising from
limitations or exceptions that are provided for in connection with the
copyright protection under copyright law or other applicable laws.
3. License Grant. Subject to the terms and conditions of this License,
Licensor hereby grants You a worldwide, royalty-free, non-exclusive,
perpetual (for the duration of the applicable copyright) license to
exercise the rights in the Work as stated below:
a. to Reproduce the Work, to incorporate the Work into one or
more Collections, and to Reproduce the Work as incorporated in
the Collections;
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b. to create and Reproduce Adaptations provided that any such
Adaptation, including any translation in any medium, takes
reasonable steps to clearly label, demarcate or otherwise identify
that changes were made to the original Work. For example, a
translation could be marked "The original work was translated
from English to Spanish," or a modification could indicate "The
original work has been modified.";
c. to Distribute and Publicly Perform the Work including as
incorporated in Collections; and,
d. to Distribute and Publicly Perform Adaptations.
e. For the avoidance of doubt:
i.
Non-waivable Compulsory License Schemes. In those
jurisdictions in which the right to collect royalties through
any statutory or compulsory licensing scheme cannot be
waived, the Licensor reserves the exclusive right to collect
such royalties for any exercise by You of the rights granted
under this License;
ii.
Waivable Compulsory License Schemes. In those
jurisdictions in which the right to collect royalties through
any statutory or compulsory licensing scheme can be
waived, the Licensor waives the exclusive right to collect
such royalties for any exercise by You of the rights granted
under this License; and,
iii.
Voluntary License Schemes. The Licensor waives the
right to collect royalties, whether individually or, in the
event that the Licensor is a member of a collecting society
that administers voluntary licensing schemes, via that
society, from any exercise by You of the rights granted
under this License.
The above rights may be exercised in all media and formats whether
now known or hereafter devised. The above rights include the right to
make such modifications as are technically necessary to exercise the
rights in other media and formats. Subject to Section 8(f), all rights
not expressly granted by Licensor are hereby reserved.
4. Restrictions. The license granted in Section 3 above is expressly
made subject to and limited by the following restrictions:
a. You may Distribute or Publicly Perform the Work only under the
terms of this License. You must include a copy of, or the Uniform
Resource Identifier (URI) for, this License with every copy of the
Work You Distribute or Publicly Perform. You may not offer or
impose any terms on the Work that restrict the terms of this
License or the ability of the recipient of the Work to exercise the
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rights granted to that recipient under the terms of the License.
You may not sublicense the Work. You must keep intact all
notices that refer to this License and to the disclaimer of
warranties with every copy of the Work You Distribute or Publicly
Perform. When You Distribute or Publicly Perform the Work, You
may not impose any effective technological measures on the
Work that restrict the ability of a recipient of the Work from You
to exercise the rights granted to that recipient under the terms
of the License. This Section 4(a) applies to the Work as
incorporated in a Collection, but this does not require the
Collection apart from the Work itself to be made subject to the
terms of this License. If You create a Collection, upon notice
from any Licensor You must, to the extent practicable, remove
from the Collection any credit as required by Section 4(b), as
requested. If You create an Adaptation, upon notice from any
Licensor You must, to the extent practicable, remove from the
Adaptation any credit as required by Section 4(b), as requested.
b. If You Distribute, or Publicly Perform the Work or any
Adaptations or Collections, You must, unless a request has been
made pursuant to Section 4(a), keep intact all copyright notices
for the Work and provide, reasonable to the medium or means
You are utilizing: (i) the name of the Original Author (or
pseudonym, if applicable) if supplied, and/or if the Original
Author and/or Licensor designate another party or parties (e.g.,
a sponsor institute, publishing entity, journal) for attribution
("Attribution Parties") in Licensor's copyright notice, terms of
service or by other reasonable means, the name of such party or
parties; (ii) the title of the Work if supplied; (iii) to the extent
reasonably practicable, the URI, if any, that Licensor specifies to
be associated with the Work, unless such URI does not refer to
the copyright notice or licensing information for the Work; and
(iv) , consistent with Section 3(b), in the case of an Adaptation,
a credit identifying the use of the Work in the Adaptation (e.g.,
"French translation of the Work by Original Author," or
"Screenplay based on original Work by Original Author"). The
credit required by this Section 4 (b) may be implemented in any
reasonable manner; provided, however, that in the case of a
Adaptation or Collection, at a minimum such credit will appear, if
a credit for all contributing authors of the Adaptation or
Collection appears, then as part of these credits and in a manner
at least as prominent as the credits for the other contributing
authors. For the avoidance of doubt, You may only use the credit
required by this Section for the purpose of attribution in the
manner set out above and, by exercising Your rights under this
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License, You may not implicitly or explicitly assert or imply any
connection with, sponsorship or endorsement by the Original
Author, Licensor and/or Attribution Parties, as appropriate, of
You or Your use of the Work, without the separate, express prior
written permission of the Original Author, Licensor and/or
Attribution Parties.
c. Except as otherwise agreed in writing by the Licensor or as may
be otherwise permitted by applicable law, if You Reproduce,
Distribute or Publicly Perform the Work either by itself or as part
of any Adaptations or Collections, You must not distort, mutilate,
modify or take other derogatory action in relation to the Work
which would be prejudicial to the Original Author's honor or
reputation. Licensor agrees that in those jurisdictions (e.g.
Japan), in which any exercise of the right granted in Section 3(b)
of this License (the right to make Adaptations) would be deemed
to be a distortion, mutilation, modification or other derogatory
action prejudicial to the Original Author's honor and reputation,
the Licensor will waive or not assert, as appropriate, this
Section, to the fullest extent permitted by the applicable national
law, to enable You to reasonably exercise Your right under
Section 3(b) of this License (right to make Adaptations) but not
otherwise.
5. Representations, Warranties and Disclaimer
UNLESS OTHERWISE MUTUALLY AGREED TO BY THE PARTIES IN
WRITING, LICENSOR OFFERS THE WORK AS-IS AND MAKES NO
REPRESENTATIONS OR WARRANTIES OF ANY KIND CONCERNING THE
WORK, EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, INCLUDING,
WITHOUT LIMITATION, WARRANTIES OF TITLE, MERCHANTIBILITY,
FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT, OR THE
ABSENCE OF LATENT OR OTHER DEFECTS, ACCURACY, OR THE
PRESENCE OF ABSENCE OF ERRORS, WHETHER OR NOT
DISCOVERABLE. SOME JURISDICTIONS DO NOT ALLOW THE
EXCLUSION OF IMPLIED WARRANTIES, SO SUCH EXCLUSION MAY
NOT APPLY TO YOU.
6. Limitation on Liability. EXCEPT TO THE EXTENT REQUIRED BY
APPLICABLE LAW, IN NO EVENT WILL LICENSOR BE LIABLE TO YOU
ON ANY LEGAL THEORY FOR ANY SPECIAL, INCIDENTAL,
CONSEQUENTIAL, PUNITIVE OR EXEMPLARY DAMAGES ARISING OUT
OF THIS LICENSE OR THE USE OF THE WORK, EVEN IF LICENSOR HAS
BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
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7. Termination
a. This License and the rights granted hereunder will terminate
automatically upon any breach by You of the terms of this
License. Individuals or entities who have received Adaptations or
Collections from You under this License, however, will not have
their licenses terminated provided such individuals or entities
remain in full compliance with those licenses. Sections 1, 2, 5, 6,
7, and 8 will survive any termination of this License.
b. Subject to the above terms and conditions, the license granted
here is perpetual (for the duration of the applicable copyright in
the Work). Notwithstanding the above, Licensor reserves the
right to release the Work under different license terms or to stop
distributing the Work at any time; provided, however that any
such election will not serve to withdraw this License (or any
other license that has been, or is required to be, granted under
the terms of this License), and this License will continue in full
force and effect unless terminated as stated above.
8. Miscellaneous
a. Each time You Distribute or Publicly Perform the Work or a
Collection, the Licensor offers to the recipient a license to the
Work on the same terms and conditions as the license granted to
You under this License.
b. Each time You Distribute or Publicly Perform an Adaptation,
Licensor offers to the recipient a license to the original Work on
the same terms and conditions as the license granted to You
under this License.
c. If any provision of this License is invalid or unenforceable under
applicable law, it shall not affect the validity or enforceability of
the remainder of the terms of this License, and without further
action by the parties to this agreement, such provision shall be
reformed to the minimum extent necessary to make such
provision valid and enforceable.
d. No term or provision of this License shall be deemed waived and
no breach consented to unless such waiver or consent shall be in
writing and signed by the party to be charged with such waiver
or consent.
e. This License constitutes the entire agreement between the
parties with respect to the Work licensed here. There are no
understandings, agreements or representations with respect to
the Work not specified here. Licensor shall not be bound by any
additional provisions that may appear in any communication
118

from You. This License may not be modified without the mutual
written agreement of the Licensor and You.
f. The rights granted under, and the subject matter referenced, in
this License were drafted utilizing the terminology of the Berne
Convention for the Protection of Literary and Artistic Works (as
amended on September 28, 1979), the Rome Convention of
1961, the WIPO Copyright Treaty of 1996, the WIPO
Performances and Phonograms Treaty of 1996 and the Universal
Copyright Convention (as revised on July 24, 1971). These rights
and subject matter take effect in the relevant jurisdiction in
which the License terms are sought to be enforced according to
the corresponding provisions of the implementation of those
treaty provisions in the applicable national law. If the standard
suite of rights granted under applicable copyright law includes
additional rights not granted under this License, such additional
rights are deemed to be included in the License; this License is
not intended to restrict the license of any rights under applicable
law.
Creative Commons Notice
Creative Commons is not a party to this License, and makes no
warranty whatsoever in connection with the Work. Creative Commons
will not be liable to You or any party on any legal theory for any
damages whatsoever, including without limitation any general, special,
incidental or consequential damages arising in connection to this
license. Notwithstanding the foregoing two (2) sentences, if Creative
Commons has expressly identified itself as the Licensor hereunder, it
shall have all rights and obligations of Licensor.
Except for the limited purpose of indicating to the public that the Work
is licensed under the CCPL, Creative Commons does not authorize the
use by either party of the trademark "Creative Commons" or any
related trademark or logo of Creative Commons without the prior
written consent of Creative Commons. Any permitted use will be in
compliance with Creative Commons' then-current trademark usage
guidelines, as may be published on its website or otherwise made
available upon request from time to time. For the avoidance of doubt,
this trademark restriction does not form part of this License.
Creative Commons may be contacted at http://creativecommons.org/.
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Abstract
Current progress in the development of vaccines has decreased
the incidence of fatal and non-fatal infections and increased longevity.
However, new technologies need to be developed to combat an
emerging generation of infectious diseases. DNA vaccination has been
demonstrated to have great potential for use with a wide variety of
diseases. Alone, this technology does not generate a significant
immune response for vaccination, but combined with delivery by
electroporation (EP), can enhance plasmid expression and immunity.
Most EP systems, while effective, can be invasive and painful making
them less desirable for use in vaccination. Our lab recently developed
a non-invasive electrode known as the multi-electrode array (MEA),
which lies flat on the surface of the skin without penetrating the tissue.
In this study we evaluated the MEA for its use in DNA vaccination
using Hepatitis B virus as the infectious model. We utilized the guinea
pig model because their skin is similar in thickness and morphology to
humans. The plasmid encoding Hepatitis B surface antigen (HBsAg)
was delivered intradermally with the MEA to guinea pig skin. The
results show increased protein expression resulting from plasmid
delivery using the MEA as compared to injection alone. Within 48
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hours of treatment, there was an influx of cellular infiltrate in
experimental groups. Humoral responses were also increased
significantly in both duration and intensity as compared to injection
only groups. While this electrode requires further study, our results
suggest that the MEA has potential for use in electrically mediated
intradermal DNA vaccination.
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Introduction
The development of vaccines is widely considered to be one of
the most important medical advancements of the 20th century.
Current methods have been pushed to the limits of their potential.
New techniques need to be developed and employed to combat a new
generation of diseases and infections. There are several advantages
to DNA vaccination. DNA vaccines are cost effective to produce, they
can be easily stored, they are highly specific and their multivalent
nature means that they could be combined to vaccinate against
several different components simultaneously [1-3]. Either due to low
expression or lack of immune recognition, injection of plasmid DNA
alone does not elicit a strong enough immune response for protective
vaccination. Electroporation (EP) is a non viral plasmid DNA delivery
approach that effectively enhances plasmid expression [4, 5] and
immunity [6-10].
EP requires the application of electric fields causing
permeabilization of the cell membranes. The permeabilized membrane
briefly contains “pores” that allow large molecules, like DNA, to enter
the cell. Initial studies evaluating in vivo EP for transgene delivery and
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expression were performed on rat brain tumors [5] and rat livers [4].
Those studies demonstrated enhanced delivery and expression of
plasmid DNA from EP mediated delivery. Successful EP mediated DNA
delivery has been demonstrated in most tissue types and for several
therapeutic and prophylactic indications such as cancer therapy,
infectious diseases, wound healing, metabolic disorders and vaccines
[11]. Recently several clinical trials have been initiated. Two clinical
trials have been completed using EP, one assessing tolerability of
intramuscular delivery [12, 13] and the other assessing toxicity and
clinical utility of delivering pIL-12 intratumorally by EP to melanoma
patients [14]. The latter demonstrated the safety, minimal toxicity,
and feasibility for the use of EP in the clinic [14]. Since the successful
completion of these studies, 19 others are currently active or
recruiting. Five of those are involving DNA vaccination against
infectious agents (clinicaltrials.gov; Keyword: Electroporation).
Initial in vivo EP DNA vaccine studies evaluated gene expression
and immune stimulation from delivery of plasmids encoding either
Hepatitis B Virus (HBV) protein or Human Immunodeficiency Virus
(HIV) protein, gag, to the muscle. Their results confirmed that
increased humoral responses to HBV [6] and cellular [9] immune
response to HIV gag from EP compared to injection only (IO) of
plasmid DNA. More recent studies have broadened the list of
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pathogens which EP has been successfully used in vivo to include other
viral pathogens such as: Simian Immunodeficiency Virus [15-18],
Severe Acute Respiratory Syndrome [19, 20], Influenza [21-25], West
Nile and Japanese Encephalitis [26, 27], as well as Hepatitis B and C
[28-32] and Human Papilloma Virus [33, 34]. EP delivered DNA
vaccines expressing proteins of the parasitic infection Plasmodium
falciparum, one of the parasites causing malaria [35], as well as
bacterial infections like Bacillus anthracis [36], Clostridium botulinum
[37], and Mycobacterium tuberculosis [38] have also been
demonstrated to enhance immunogenicity. These results demonstrate
the capacity of EP to enhance not only gene delivery and protein
expression but also its ability to stimulate the host immune response
against a wide variety of pathogens.
Current electrically mediated DNA vaccines employ painful
invasive needle electrodes that are inserted into the muscle for
electrical stimulation. The primary tissue used for in vivo EP is muscle
because it is accessible, highly vascularized, multinucleated, and
expresses DNA for long periods of time due to the post-mitotic nature
of the tissue [39]. However, pain associated with administration is not
desirable. As such, alternative delivery sites and methods have been
explored. The skin is an attractive target for vaccination because of
the high proportion of antigen presenting cells (APC) and large surface
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area. Recent studies, as well as work done in our laboratory,
demonstrated that intradermal electrically mediated DNA expression
can be increased both locally and systemically [8, 40-44]. Electrodes
developed for skin EP include: caliper, plate, tweezer, and clip
electrodes as well as several needle electrodes [14, 45-48].
To develop an electrically mediated intradermal DNA vaccine we
utilized the non-invasive multi-electrode array (MEA), shown in figure
1, for EP delivery. The MEA has 16 electrodes placed 2mm apart and
is arranged in 4 rows [45]. Pulses are administered in a sequence that
utilizes 4 electrodes at a time, forming 2 X 2 mm squares (9 total
squares). Pulses are applied in pairs, in two directions, perpendicular
to each other (18 pulses) for 4 rounds of pulsing (72 total pulses).
While we have not as yet modeled or directly measured the fields
generated across the treated area of skin, we believe by applying the
field across a smaller area (2 X 2 mm) will facilitate obtaining a more
uniform field then would be obtained when the field is applied across
the entire treated area (6 X 6 mm). Our lab previously demonstrated
that this electrode, when used in a guinea pig skin model, could
significantly increase reporter gene activity [45]. Conditions required
for optimal expression were determined to be between 200-300 V/cm
and 150ms.
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An additional consideration for establishing a MEA delivered DNA
vaccine is choosing the appropriate animal model. Guinea pig skin is
similar to human skin in thickness and morphology [49]. For this
reason, we selected the guinea pig model to better evaluate our
delivery approach utilizing a small animal model with skin similar to
humans. Therefore, the goal of this study was to evaluate intradermal
MEA EP delivery of Hepatitis B surface antigen in a human-like skin
model.
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Methods
2.1 Ethics Statement: All animal procedures were conducted in a
facility (USF) that is fully accredited by the Association for the
Assessment and Accreditation of Laboratory Animal Care (AAALAC)
and the Public Health Service (PHS). Research was conducted under a
protocol approved by the Institutional Animal Care and Use Committee
(IACUC) at the University of South Florida, College of Medicine
(protocol # 2879). All animals were housed, handled and utilizing
following guidelines of the United States National Institutes of Health.

2.2 Animals: Female Hartley guinea pigs between 200-250g were used
in this study to evaluate skin EP conditions. Guinea pigs were housed
at the University of South Florida, College of Medicine vivarium and
were rested for one week prior to experimentation. Guinea pigs were
anesthetized with 2.5-3.0% isoflurane before and during all
procedures. No previous exposure to Hepatitis B virus was known.

2.3 Plasmid: The plasmid used in this study was gWiz™ HBsAg
(Aldevron, Fargo, ND). This plasmid encodes for the surface antigen
of Hepatitis B and is driven by the CMV promoter.
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2.4 Immunization: All guinea pigs were intradermally injected with
100µg (2mg/ml) of gWiz™ HBsAg at two sites on the left flank. MEA
EP was performed at 300V/cm and 150ms and 72 pulses. The two
groups used in this study were control group injection of plasmid only
(IO) and injection of plasmid plus EP (I +EP). All groups were boosted
with the same condition at Day 14.

2.5 serum collection: Guinea pigs were bled through the jugular vein
at various time points from Day 0 through Day 168. Blood was
collected and serum isolated in serum separator tubes. Serum was
diluted two-fold starting at 1:10.

2.6 Tissue collection: Guinea pigs were treated as described with
gWiz™ HBsAg with and without EP. Those guinea pigs whose tissue
was collected for plasmid expression were sacrificed 48 hours after one
treatment and skin samples were harvested by excising the treatment
site and snap frozen. Those guinea pigs whose tissue was collected to
assess damage and cell infiltrate were treated and harvested 96 hours
after one treatment and the tissue was snap frozen.

2.7 Indirect ELISA for the detection of Hepatitis B surface antigen
antibodies: The enzyme linked immunosorbant assay (ELISA) was
129

used to assess the production of antibodies from treatment and
performed per manufacturer’s protocol (Aldevron). Briefly, a 96-well
plate (Nunc) was coated with 10µg/ml of Hepatitis B surface antigen
(Aldevron) and allowed to coat overnight at 4°C. The plate was
blocked with 3% BSA in PBST for 2 hours at 37°C. Serum samples
were two-fold diluted in blocking buffer and added to the plate for 2
hours at 37°C. Goat anti-Guinea pig-AP antibody was added at a
1:10000 dilution in blocking buffer. AP substrate, pNPP, (Sigma) was
added to colorize and the plate was read at 405nm.

2.8 Immunohistochemistry: Pathological analysis of the skin sections
was performed to determine the extent of plasmid expression as well
as inflammation and tissue damage. An anti-HBsAg was used to
detect plasmid expression. Skin samples taken 48 hours after
treatment were frozen, sectioned, and placed on slides. Slides were
rehydrated and then blocked with 3% BSA in PBST and incubated in a
humidifying chamber for 1 hr. A HRP conjugated anti-HBsAg
(AbDSerotec) was made in blocking buffer at a 1:200 dilution. All
samples were counterstained with Hematoxylin& Eosin. Samples
collected at 96 hours frozen, sectioned, and placed on slides were
stained with H & E to determine the extent of cellular
infiltrate/inflammation.
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2.9 Statistical analysis: All Guinea pigs were bled at Day 0 to
determine background optical density (OD). OD’s were averaged and
2 standard deviations added to determine positive (0.1 OD).
Experimental serum samples were diluted two-fold starting at 1:10.
End point titers were calculated and plotted as Geometric Means.
Significance was determined by student t-test using the bonferroni
correction for multiple comparisons.
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Results
3.1 Plasmid expression from EP.
The first step in evaluating the MEA for delivery of DNA vaccines
in a human-like model was to determine the expression levels of
gWiz™ HBsAg. Guinea pigs were treated as described with or without
EP using the MEA. 48 hours after delivery the guinea pigs were
euthanized and the treated skin harvested and processed for
histological evaluation. Expression of HBsAg was determined by
immunohistochemistry. Expression of HBsAg is seen in IO and I+EP
(Fig 1a and b), however increased staining was observed in the I+EP
samples. Expression is contained within the epidermis of IO animals.
When compared to I+EP animals expression can be seen within the
epidermis and dermis.

3.2 Immune cell infiltrate and tissue damage
To determine whether EP with the MEA would recruit immune
cells to the treatment site and cause inflammation, guinea pigs were
treated as described and tissue samples harvested 96 hours after
treatment. Samples were stained with H&E to assess cellular infiltrate,
damage, and necrosis from treatment. The induction of immune
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stimulation is important for vaccines in general, but can be limited for
DNA vaccines. Induction of immune cell infiltrate was observed (Fig 2
C-F 100X magnification). Background levels, Fig 2c, of infiltrate are
demonstrated in no treatment control and correspond to low levels of
cellular infiltrate (purple). IO samples show slight increases in
infiltrate as compared to no treatment, Fig 2d. In contrast, I+EP
samples show a large increase in cellular infiltrate, Fig 2e. I + EP
groups contained primarily macrophages and multi-lobed cells, most
likely activated neutrophils (200x magnification Fig. 2f), corresponding
to a prolonged inflammatory immune response [50].
Edema was seen in all samples except no treatment controls;
and did not appear increased due to EP. This is most likely a result
from the injection of plasmid into the tissue. In most samples tissue
damage and necrosis were not seen. However, two EP delivered
samples had minimal ulcerations at 96 hours after treatment, one of
which also had about 1% necrosis. There were no other samples
showing damage or necrosis (data not shown). Gross evaluation of
the skin shows no difference between IO and I+EP groups over time
(Fig 3). Complete visual recovery of the skin is seen by Day 7.

133

3.3 Anti-Hepatitis B surface antigen antibodies
While cellular infiltrate can be an early indicator of immunity, a
more accurate measure is the induction of specific antibodies
generated against HBsAg. Anti-HBs were measured by ELISA over
time. Guinea pigs, treated and serum collected as described in
methods, showed significant increases in antibody expression from
three weeks after initial treatment through week 24. The data
collected was from 3 independent experiments (n=6 for each
experiement) with a total n of 18 for both IO and EP groups. Peak
expression for both groups occurred at week 18 with IO groups having
a GMT of 1000 and I+EP animals at 5000 (Fig 4). The fold increase
over IO remained relatively constant at about 5 fold with the greatest
fold increase over IO of 6.5 occurring at week 18.
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Discussion
These data demonstrate that the MEA can be effective for the
use in electrically mediated DNA vaccination in a human-like skin
model. EP with the MEA generated increased plasmid expression as
well as an increase in immune infiltrate after treatment. The
magnitude of immune infiltrate was greater in EP groups than IO and
there was minimal to no skin damage associated. Specific, lasting,
and significant levels of antibodies were greater than IO. This is the
first report to demonstrate the use of the MEA for DNA vaccination in a
human-like skin model.
DNA vaccination is advantageous because it does not integrate
into the host DNA, it is cost effective to produce and easily stored, it
can be highly specific for tissue and/or cell type and can be made to
vaccinate against multiple agents simultaneously. The skin is an ideal
target for DNA vaccination due to the large surface area and presence
of antigen presenting cells like langerhan’s and dermal dendritic cells,
specialized for induction of immunity [51]. However, injection of
plasmid alone does not induce high enough immune responses to be
protective. EP is one method that has been shown to increase both
plasmid expression as well as immunity.
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Previous EP methods have involved painful penetrating
electrodes that go into the muscle to facilitate delivery. Further
advancements have been made using non-penetrating electrodes such
as caliper and plate electrodes. However, these electrodes require
high voltages to enhance delivery and therefore can cause tissue
damage. In this study, we have evaluated a non-penetrating electrode
which reduces the gap width between electrodes to 2mm thereby
reducing the absolute voltage applied and preventing visible tissue
damage while still increasing plasmid expression and immunity.
As expected from our previous publication [45], EP with the MEA
enhanced expression. While the exact reason for the effectiveness of
EP remains unknown, increased plasmid expression at least in the case
of DNA vaccination, plays an important role in recognition by the
immune system [52]. EP has been shown to have an adjuvant effect
by recruiting immune cells to the site of pulse application [53]. In our
study, we saw an influx of nucleated cells from EP treated samples.
These cells are most likely neutrophils and macrophages based on
morphology. This is most likely a combination of both an EP mediated
adjuvant effect and increased plasmid expression. The induction of
macrophages and polymorpho-nucleated neutrophils is indicative of a
chronic inflammatory response. While the perception of prolonged
inflammation is typically negative in our case it indicates that the
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expression of the plasmid is present for a prolonged period of time,
giving the immune response enough time to perform its function.
Based on our earlier work [45] we would expect this prolonged
expression to decrease after approximately 14 days, therefore allowing
the body to heal and not generate deleterious effects from
inflammation.
These findings seem to correlate with our antibody data, where
an increase in the presence of specific antibodies was measured over
time. These antibodies were significantly increased as compared to
injection only. Geometric mean titers ranged from 4000-16000
peaking at week 18. Antibody levels remained elevated until dropping
off after week 21, but still remained increased as compared to
injection only. The enhanced intensity of humoral immunity by EP
with the MEA corresponds to previously published skin EP results [5457]. One of the primary reasons for evaluating our delivery method
with Hepatitis B was because it is a well characterized vaccination
model. Published studies have reported geometric mean titers in
conjunction with protective efficacy in guinea pigs. While the
presented GMT’s in these papers were higher than ours, they also
reported protective levels more than 100 fold above the necessary
levels. Our GMT’s are likely to still be within the protective range
without generating unnecessary additional responses [58, 59].
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Comparing specifically to Hepatitis B DNA vaccines delivered by EP
several animal models have been evaluated and EP has been shown to
have protective levels from 10-1000mIU/ml [6, 9, 32, 60, 61]. The
most recent comparable publication evaluated a minimally invasive
device for protective vaccination against influenza [62]. While their
results were only presented as neutralizing titers against flu and
cannot be compared directly we believe that our electrode design
generates immune responses of equal quality without tissue
penetration.
The data represented here demonstrate the capability of the
MEA to increase plasmid expression, immune cell infiltrate and
inflammatory response, as well as antibody production over 24 weeks
in a human-like skin model. This information presents a potential new
method for DNA vaccination that may be translatable to humans.
Further studies will examine the MEA for use in DNA vaccination
against other infectious agents.
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Figure legends
Fig. 1 Non-invasive Multi-Electrode Array. The MEA has 16 electrodes
placed 2mm apart and is arranged in 4 rows. Pulses are administered
in a sequence that utilizes 4 electrodes at a time, forming 2 X 2 mm
squares (9 total squares). Pulses are applied in pairs, in two
directions, perpendicular to each other (18 pulses) for 4 rounds of
pulsing (72 total pulses). This image is reprinted from The Journal of
Controlled Release doi:10.1016/j.jconrel.2011.01.014 Siqi Guo, Amy
Donate, Guarav Basu, Cathryn Lundberg, Loree Heller, Richard Heller
“Electro-gene transfer to the skin using a non-invasive multi-electrode
array” with permission from Elsevier.

Fig. 2 Plasmid expression and inflammation in the skin.
Guinea pigs were treated as described in Methods 2.1 with pHBsAg.
Expression of plasmid was evaluated at 48 hrs post treatment by IHC
(A-IO; B I + EP). Inflammation was measured 96 hrs post treatment
and assessed by H&E (C-No treatment; D- IO, E – I + EP) at 100X
magnification and 200X magnification (F- I + EP).
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Fig. 3 Visual assessment of skin damage and healing.
Guinea pigs were treated as described in Methods 2.1 with pHBsAg
with or without EP. Images were taken of skin pre treatment,
immediately post treatment, and at 24, 48, 72, 96 hours and at 7
days. Arrows indicate the treatment sites.

Fig. 4 Evaluation of anti-HBs serum titer.
Guinea pigs were treated as described in Methods 2.1 with pHBsAg.
Serum was collected at multiple time points and an ELISA performed.
Geometric mean titers are expressed. Positive was determined by two
standard deviations greater than the Day 0 OD. IO and EP n=6 for
each experiment with 3 independent experiments conducted (total
n=18). Statistics were determined by two-sided student t-test with
bonferroni correction to p<0.05.
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